1
|
Gutiérrez MC, Cáceres A, Herruzo-Ruiz AM, Siles JA, Vázquez F, Alhama J, Michán C, Martín MA. Assessment of nitrification process in a sequencing batch reactor: Modelling and genomic approach. Environ Res 2024; 246:118035. [PMID: 38199477 DOI: 10.1016/j.envres.2023.118035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 12/19/2023] [Accepted: 12/22/2023] [Indexed: 01/12/2024]
Abstract
Nitrification of ammoniacal nitrogen (N-NH4+) to nitrate (N-NO3-) was investigated in a lab-scale sequencing batch reactor (SBR) to evaluate its efficiency. During the nitrification process the removal of N-NH4+ reached 96%, resulting in 73% formation of N-NO3-. A lineal correlation (r2 = 0.9978) was obtained between the concentration of volatile suspended solids (VSS) and the maximal N-NO3- concentration at the end of each batch cycle under stationary state. The bacterial taxons in the initial inoculum were identified, revealing a complex diverse community mainly in the two major bacterial phyla Proteobacteria and Actinobacteria. The FAPROTAX algorithm predicted the presence in the inoculum of taxa involved in relevant processes of the nitrogen metabolism, highlighting the bacterial genera Nitrospira and Nitrosomonas that are both involved in the nitrification process. A kinetic model was formulated for predicting and validating the transformation of N-NH4+, N-NO2- and N-NO3- and the removal of organic and inorganic carbon (TOC and IC, respectively). The results showed how the increase in biomass concentration slowed down the transformation to oxidised forms of nitrogen and increased denitrification in the settling and filling stages under free aeration conditions.
Collapse
Affiliation(s)
- M C Gutiérrez
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, edificio Marie Curie, 14071, Córdoba, Spain
| | - A Cáceres
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, edificio Marie Curie, 14071, Córdoba, Spain
| | - A M Herruzo-Ruiz
- Department of Biochemistry and Molecular Biology, University of Cordoba, Campus de Excelencia Internacional Agroalimentario ceiA3, edificio Severo Ochoa, 14071, Córdoba, Spain
| | - J A Siles
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, edificio Marie Curie, 14071, Córdoba, Spain
| | - F Vázquez
- Department of Electrical Engineering and Automation, University of Cordoba, Cordoba, 14071, Spain
| | - J Alhama
- Department of Biochemistry and Molecular Biology, University of Cordoba, Campus de Excelencia Internacional Agroalimentario ceiA3, edificio Severo Ochoa, 14071, Córdoba, Spain
| | - C Michán
- Department of Biochemistry and Molecular Biology, University of Cordoba, Campus de Excelencia Internacional Agroalimentario ceiA3, edificio Severo Ochoa, 14071, Córdoba, Spain
| | - M A Martín
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, edificio Marie Curie, 14071, Córdoba, Spain.
| |
Collapse
|
2
|
Guerrero-Molina MP, Bernabeu-Sanz Á, Ramos-González A, Morales-Conejo M, Delmiro A, Domínguez-González C, Arenas J, Martín MA, González de la Aleja J. Magnetic resonance spectroscopy in MELAS syndrome: correlation with CSF and plasma metabolite levels and change after glutamine supplementation. Neuroradiology 2024; 66:389-398. [PMID: 38114794 DOI: 10.1007/s00234-023-03263-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 12/02/2023] [Indexed: 12/21/2023]
Abstract
PURPOSE MELAS syndrome is a genetic disorder caused by mitochondrial DNA mutations. We previously described that MELAS patients had increased CSF glutamate and decreased CSF glutamine levels and that oral glutamine supplementation restores these values. Proton magnetic resonance spectroscopy (1H-MRS) allows the in vivo evaluation of brain metabolism. We aimed to compare 1H-MRS of MELAS patients with controls, the 1H-MRS after glutamine supplementation in the MELAS group, and investigate the association between 1H-MRS and CSF lactate, glutamate, and glutamine levels. METHODS We conducted an observational case-control study and an open-label, single-cohort study with single-voxel MRS (TE 144/35 ms). We assessed the brain metabolism changes in the prefrontal (PFC) and parieto-occipital) cortex (POC) after oral glutamine supplementation in MELAS patients. MR spectra were analyzed with jMRUI software. RESULTS Nine patients with MELAS syndrome (35.8 ± 3.2 years) and nine sex- and age-matched controls were recruited. Lactate/creatine levels were increased in MELAS patients in both PFC and POC (0.40 ± 0.05 vs. 0, p < 0.001; 0.32 ± 0.03 vs. 0, p < 0.001, respectively). No differences were observed between groups in glutamate and glutamine (Glx/creatine), either in PFC (p = 0.930) or POC (p = 0.310). No differences were observed after glutamine supplementation. A positive correlation was found between CSF lactate and lactate/creatine only in POC (0.85, p = 0.003). CONCLUSION No significant metabolite changes were observed in the brains of MELAS patients after glutamine supplementation. While we found a positive correlation between lactate levels in CSF and 1H-MRS in MELAS patients, we could not monitor treatment response over short periods with this tool. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04948138; initial release 24/06/2021; first patient enrolled on 1/07/2021. https://clinicaltrials.gov/ct2/show/NCT04948138.
Collapse
Affiliation(s)
- María Paz Guerrero-Molina
- Neurology Department, Neuromuscular Disorders Unit, University Hospital, 12 de Octubre Avda. de Córdoba, S/N 28041, Madrid, Spain.
| | | | - Ana Ramos-González
- Department of Neuroradiology, University Hospital, 12 de Octubre, Madrid, Spain
| | - Montserrat Morales-Conejo
- Department of Internal Medicine, University Hospital, 12 de Octubre, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
| | - Aitor Delmiro
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital, 12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Cristina Domínguez-González
- Neurology Department, Neuromuscular Disorders Unit, University Hospital, 12 de Octubre Avda. de Córdoba, S/N 28041, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Joaquín Arenas
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital, 12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Miguel A Martín
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital, 12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Jesús González de la Aleja
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
- Neurology Department, Epilepsy Unit, University Hospital, 12 de Octubre, Madrid, Spain
| |
Collapse
|
3
|
Martínez-Alvarenga H, Gutiérrez MC, Gómez-Cámer JL, Benítez A, Martín MA, Caballero A. Integral evaluation of effective conversion of sewage sludge from WWTP into highly porous activated carbon. J Environ Manage 2024; 351:119822. [PMID: 38134504 DOI: 10.1016/j.jenvman.2023.119822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 11/24/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023]
Abstract
Urban sewage sludge (SL) is a major concern due to the number of environmental problems it causes. Its application for different purposes is strictly regulated, limiting the possibilities of recycling and reusing this material. Thus, in this work, a complete study of a simple method to convert SL into activated carbon (AC) was carried out. The comprehensive study involves an evaluation of the main process parameters, such as the activating agent (AA) content (25 %, 33 %, 50 %), using the lowest amount of AA as novelty, different pyrolysis temperatures (600 and 800 °C), and purification conditions (6 M HCl:AC ratio, v:w). Under controlled and optimised conditions and through a single combined activation and pyrolysis step followed by acid purification, ACs with well-developed porosity can be obtained. Surface area values of around 870 m2/g and over 60 % carbon content were achieved, demonstrating that the prepared ACs could have applications in a wide variety of fields as high-value products. As an innovative aspect in this research, the gases streams and liquid effluents generated during the global process were analysed, achieving elimination of over 63 % of the concentration of the chemical elements contained in the SL during the chemical purification stage. Finally, mass, energy, and economic balances were carried out to estimate the production cost of AC derived from SL (<€ 8/kg AC).
Collapse
Affiliation(s)
- H Martínez-Alvarenga
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Universidad de Córdoba, 14014, Córdoba, Spain
| | - M C Gutiérrez
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Universidad de Córdoba, 14014, Córdoba, Spain; Campus de Excelencia Internacional Agroalimentario ceiA3, Universidad de Córdoba, Campus Universitario de Rabanales, N-IV, km 396, Córdoba, 14071, Spain
| | - J L Gómez-Cámer
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Universidad de Córdoba, 14014, Córdoba, Spain
| | - A Benítez
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Universidad de Córdoba, 14014, Córdoba, Spain.
| | - M A Martín
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Universidad de Córdoba, 14014, Córdoba, Spain; Campus de Excelencia Internacional Agroalimentario ceiA3, Universidad de Córdoba, Campus Universitario de Rabanales, N-IV, km 396, Córdoba, 14071, Spain.
| | - A Caballero
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Químico para la Energía y el Medioambiente (IQUEMA), Universidad de Córdoba, 14014, Córdoba, Spain
| |
Collapse
|
4
|
Serrano-Lorenzo P, Gobelli D, Garrido-Moraga R, Esteban-Amo MJ, López-López JR, Orduña A, de la Fuente MA, Martín MA, Simarro M. Development of a novel in vitro model to study the modulatory role of the respiratory complex I in macrophage effector functions. PLoS One 2023; 18:e0291442. [PMID: 37725617 PMCID: PMC10508620 DOI: 10.1371/journal.pone.0291442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Accepted: 08/29/2023] [Indexed: 09/21/2023] Open
Abstract
Increasing evidence demonstrate that the electron transfer chain plays a critical role in controlling the effector functions of macrophages. In this work, we have generated a Ndufs4-/- murine macrophage cell lines. The Ndufs4 gene, which encodes a supernumerary subunit of complex I, is a mutational hotspot in Leigh syndrome patients. Ndufs4-/- macrophages showed decreased complex I activity, altered complex I assembly, and lower levels of maximal respiration and ATP production. These mitochondrial respiration alterations were associated with a shift towards a pro-inflammatory cytokine profile after lipopolysaccharide challenge and improved ability to phagocytose Gram-negative bacteria.
Collapse
Affiliation(s)
- Pablo Serrano-Lorenzo
- Hospital 12 de Octubre Research Institute (imas12), Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Dino Gobelli
- Department of Cell Biology, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, Spain
- Unit of Excellence Institute of Biomedicine and Molecular Genetics (IBGM), University of Valladolid and Spanish National Research Council (CSIC), Valladolid, Spain
| | - Rocío Garrido-Moraga
- Hospital 12 de Octubre Research Institute (imas12), Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - María J. Esteban-Amo
- Department of Cell Biology, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, Spain
- Unit of Excellence Institute of Biomedicine and Molecular Genetics (IBGM), University of Valladolid and Spanish National Research Council (CSIC), Valladolid, Spain
| | - José R. López-López
- Unit of Excellence Institute of Biomedicine and Molecular Genetics (IBGM), University of Valladolid and Spanish National Research Council (CSIC), Valladolid, Spain
- Department of Department of Biochemistry and Molecular Biology and Physiology, Faculty of Medicine, University of Valladolid, Valladolid, Spain
| | - Antonio Orduña
- Division of Microbiology, Hospital Clínico of Valladolid, Valladolid, Spain
- Department of Microbiology, University of Valladolid, Valladolid, Spain
| | - Miguel A. de la Fuente
- Department of Cell Biology, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, Spain
- Unit of Excellence Institute of Biomedicine and Molecular Genetics (IBGM), University of Valladolid and Spanish National Research Council (CSIC), Valladolid, Spain
| | - Miguel A. Martín
- Hospital 12 de Octubre Research Institute (imas12), Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - María Simarro
- Department of Cell Biology, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, Spain
- Unit of Excellence Institute of Biomedicine and Molecular Genetics (IBGM), University of Valladolid and Spanish National Research Council (CSIC), Valladolid, Spain
| |
Collapse
|
5
|
González-Quintana A, Garrido-Moraga R, Palencia-Pérez SI, Hernández-Martín Á, Sánchez-Munárriz J, Lezana-Rosales JM, Quesada-Espinosa JF, Martín MA, Arteche-López A. Integration of Phenotype Term Prioritization and Gene Expression Analysis Reveals a Novel Variant in the PERP Gene Associated with Autosomal Recessive Erythrokeratoderma. Genes (Basel) 2023; 14:1494. [PMID: 37510397 PMCID: PMC10379359 DOI: 10.3390/genes14071494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 07/18/2023] [Accepted: 07/19/2023] [Indexed: 07/30/2023] Open
Abstract
Hereditary palmoplantar keratodermas (PPKs) are a clinically and genetically heterogeneous group of disorders characterized by excessive epidermal thickening of palms and soles. Several genes have been associated with PPK including PERP, a gene encoding a crucial component of desmosomes that has been associated with dominant and recessive keratoderma. We report a patient with recessive erythrokeratoderma (EK) in which whole exome sequencing (WES) prioritized by human phenotype ontology (HPO) terms revealed the presence of the novel variant c.153C > A in the N-terminal region the PERP gene. This variant is predicted to have a nonsense effect, p.(Cys51Ter), resulting in a premature stop codon. We demonstrated a marked reduction in gene expression in cultured skin fibroblasts obtained from the patient. Despite the PERP gene is expressed at low levels in fibroblasts, our finding supports a loss-of-function (LoF) mechanism for the identified variant, as previously suggested in recessive EK. Our study underscores the importance of integrating HPO analysis when using WES for molecular genetic diagnosis in a clinical setting, as it facilitates continuous updates regarding gene-clinical feature associations.
Collapse
Affiliation(s)
- Adrián González-Quintana
- Servicio Bioquímica Clínica/Análisis Clínicos, Hospital 12 de Octubre, 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
- Grupo de Enfermedades Mitocondriales y Neurometabólicas, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
| | - Rocío Garrido-Moraga
- Grupo de Enfermedades Mitocondriales y Neurometabólicas, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
| | - Sara I Palencia-Pérez
- Departamento de Dermatología, Hospital Universitario 12 de Octubre y Universidad Complutense de Madrid, 28041 Madrid, Spain
| | - Ángela Hernández-Martín
- Departamento de Dermatología, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain
| | - Jon Sánchez-Munárriz
- Servicio Bioquímica Clínica/Análisis Clínicos, Hospital 12 de Octubre, 28041 Madrid, Spain
| | - José M Lezana-Rosales
- Servicio de Genética, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- UDisGen (Unidad de Dismorfología y Genética), Hospital 12 de Octubre, 28041 Madrid, Spain
| | - Juan F Quesada-Espinosa
- Servicio de Genética, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- UDisGen (Unidad de Dismorfología y Genética), Hospital 12 de Octubre, 28041 Madrid, Spain
| | - Miguel A Martín
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
- Grupo de Enfermedades Mitocondriales y Neurometabólicas, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Servicio de Genética, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- UDisGen (Unidad de Dismorfología y Genética), Hospital 12 de Octubre, 28041 Madrid, Spain
| | - Ana Arteche-López
- Servicio de Genética, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- UDisGen (Unidad de Dismorfología y Genética), Hospital 12 de Octubre, 28041 Madrid, Spain
| |
Collapse
|
6
|
Muñoz-García MI, Guerrero-Molina MP, de Fuenmayor-Fernández de la Hoz CP, Bermejo-Guerrero L, Arteche-López A, Hernández-Laín A, Martín MA, Domínguez-González C. Delayed Diagnosis of Congenital Myasthenic Syndromes Erroneously Interpreted as Mitochondrial Myopathies. J Clin Med 2023; 12:jcm12093308. [PMID: 37176748 PMCID: PMC10179722 DOI: 10.3390/jcm12093308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Revised: 04/02/2023] [Accepted: 05/04/2023] [Indexed: 05/15/2023] Open
Abstract
BACKGROUND Congenital myasthenic syndromes (CMSs) and primary mitochondrial myopathies (PMMs) can present with ptosis, external ophthalmoplegia, and limb weakness. METHODS Our method involved the description of three cases of CMS that were initially characterized as probable PMM. RESULTS All patients were male and presented with ptosis and/or external ophthalmoplegia at birth, with proximal muscle weakness and fatigue on physical exertion. After normal repetitive nerve stimulation (RNS) studies performed on facial muscles, a muscle biopsy (at a median age of 9) was performed to rule out congenital myopathies. In all three cases, the biopsy findings (COX-negative fibers or respiratory chain defects) pointed to PMM. They were referred to our neuromuscular unit in adulthood to establish a genetic diagnosis. However, at this time, fatigability was evident in the physical exams and RNS in the spinal accessory nerve showed a decremental response in all cases. Targeted genetic studies revealed pathogenic variants in the MUSK, DOK7, and RAPSN genes. The median diagnostic delay was 29 years. Treatment resulted in functional improvement in all cases. CONCLUSIONS Early identification of CMS is essential as medical treatment can provide clear benefits. Its diagnosis can be challenging due to phenotypic overlap with other debilitating disorders. Thus, a high index of suspicion is necessary to guide the diagnostic strategy.
Collapse
Affiliation(s)
- Mariana I Muñoz-García
- Neuromuscular Unit, Neurology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | | | | | - Laura Bermejo-Guerrero
- Neuromuscular Unit, Neurology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | - Ana Arteche-López
- Genetics Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | | | - Miguel A Martín
- Genetics Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), 28041 Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Research Group, 12 de Octubre, Hospital Research Institute (imas12), 28041 Madrid, Spain
| | - Cristina Domínguez-González
- Neuromuscular Unit, Neurology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), 28041 Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Research Group, 12 de Octubre, Hospital Research Institute (imas12), 28041 Madrid, Spain
| |
Collapse
|
7
|
Bermejo-Guerrero L, de Fuenmayor-Fernández de la Hoz CP, Guerrero-Molina MP, Martín-Jiménez P, Blázquez A, Serrano-Lorenzo P, Lora D, Morales-Conejo M, González-Martínez I, López-Jiménez EA, Martín MA, Domínguez-González C. Serum GDF-15 Levels Accurately Differentiate Patients with Primary Mitochondrial Myopathy, Manifesting with Exercise Intolerance and Fatigue, from Patients with Chronic Fatigue Syndrome. J Clin Med 2023; 12:jcm12062435. [PMID: 36983435 PMCID: PMC10059275 DOI: 10.3390/jcm12062435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 03/14/2023] [Accepted: 03/20/2023] [Indexed: 03/30/2023] Open
Abstract
Primary mitochondrial myopathies (PMM) are a clinically and genetically highly heterogeneous group that, in some cases, may manifest exclusively as fatigue and exercise intolerance, with minimal or no signs on examination. On these occasions, the symptoms can be confused with the much more common chronic fatigue syndrome (CFS). Nonetheless, other possibilities must be excluded for the final diagnosis of CFS, with PMM being one of the primary differential diagnoses. For this reason, many patients with CFS undergo extensive studies, including extensive genetic testing and muscle biopsies, to rule out this possibility. This study evaluated the diagnostic performance of growth differentiation factor-15 (GDF-15) as a potential biomarker to distinguish which patient with chronic fatigue has a mitochondrial disorder. We studied 34 adult patients with symptoms of fatigue and exercise intolerance with a definitive diagnosis of PMM (7), CFS (22), or other non-mitochondrial disorders (5). The results indicate that GDF-15 can accurately discriminate between patients with PMM and CFS (AUC = 0.95) and between PMM and patients with fatigue due to other non-mitochondrial disorders (AUC = 0.94). Therefore, GDF-15 emerges as a promising biomarker to select which patients with fatigue should undergo further studies to exclude mitochondrial disease.
Collapse
Affiliation(s)
- Laura Bermejo-Guerrero
- Neuromuscular Disorders Unit, Department of Neurology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | | | - María Paz Guerrero-Molina
- Neuromuscular Disorders Unit, Department of Neurology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | | | - Alberto Blázquez
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Clinical Research Unit, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain
| | - Pablo Serrano-Lorenzo
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Clinical Research Unit, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain
| | - David Lora
- Clinical Research Unit, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain
- Department of Statistics and Data Science, Facultad de Estudios Estadísticos, Universidad Complutense de Madrid, 28040 Madrid, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Montserrat Morales-Conejo
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Internal Medicine Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Congenital Metabolic Defects Group, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | | | | | - Miguel A Martín
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Genetics Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | - Cristina Domínguez-González
- Neuromuscular Disorders Unit, Department of Neurology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain
| |
Collapse
|
8
|
Guerrero-Molina MP, Morales-Conejo M, Delmiro A, Morán M, Domínguez-González C, Arranz-Canales E, Ramos-González A, Arenas J, Martín MA, de la Aleja JG. High-dose oral glutamine supplementation reduces elevated glutamate levels in cerebrospinal fluid in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome. Eur J Neurol 2023; 30:538-547. [PMID: 36334048 DOI: 10.1111/ene.15626] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 10/07/2022] [Accepted: 10/27/2022] [Indexed: 11/08/2022]
Abstract
BACKGROUND AND PURPOSE Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder caused by mitochondrial DNA mutations. There are no disease-modifying therapies, and treatment remains mainly supportive. It has been shown previously that patients with MELAS syndrome have significantly increased cerebrospinal fluid (CSF) glutamate and significantly decreased CSF glutamine levels compared to controls. Glutamine has many metabolic fates in neurons and astrocytes, and the glutamate-glutamine cycle couples with many metabolic pathways depending on cellular requirements. The aim was to compare CSF glutamate and glutamine levels before and after dietary glutamine supplementation. It is postulated that high-dose oral glutamine supplementation could reduce the increase in glutamate levels. METHOD This open-label, single-cohort study determined the safety and changes in glutamate and glutamine levels in CSF after 12 weeks of oral glutamine supplementation. RESULTS Nine adult patients with MELAS syndrome (66.7% females, mean age 35.8 ± 3.2 years) were included. After glutamine supplementation, CSF glutamate levels were significantly reduced (9.77 ± 1.21 vs. 18.48 ± 1.34 μmol/l, p < 0.001) and CSF glutamine levels were significantly increased (433.66 ± 15.31 vs. 336.31 ± 12.92 μmol/l, p = 0.002). A side effect observed in four of nine patients was a mild sensation of satiety. One patient developed mild and transient elevation of transaminases, and another patient was admitted for an epileptic status without stroke-like episode. DISCUSSION This study demonstrates that high-dose oral glutamine supplementation significantly reduces CSF glutamate and increases CSF glutamine levels in patients with MELAS syndrome. These findings may have potential therapeutic implications in these patients. TRIAL REGISTRATION INFORMATION ClinicalTrials.gov Identifier: NCT04948138. Initial release 24 June 2021, first patient enrolled 1 July 2021. https://clinicaltrials.gov/ct2/show/NCT04948138.
Collapse
Affiliation(s)
| | - Montserrat Morales-Conejo
- Department of Internal Medicine, University Hospital, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) and European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
| | - Aitor Delmiro
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - María Morán
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Cristina Domínguez-González
- Neurology Department, Neuromuscular Disorders Unit, University Hospital, Madrid, Spain
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Elena Arranz-Canales
- Department of Internal Medicine, University Hospital, Madrid, Spain
- National Reference Center for Congenital Errors of Metabolism (CSUR) and European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, Madrid, Spain
| | | | - Joaquín Arenas
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Miguel A Martín
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
- Research Institute ('imas12'), University Hospital, Madrid, Spain
| | - Jesús González de la Aleja
- National Reference Center for Congenital Errors of Metabolism (CSUR) and European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, Madrid, Spain
- Neurology Department, Epilepsy Unit, University Hospital, Madrid, Spain
| |
Collapse
|
9
|
Amate-García G, Ballesta-Martínez MJ, Serrano-Lorenzo P, Garrido-Moraga R, González-Quintana A, Blázquez A, Rubio JC, García-Consuegra I, Arenas J, Ugalde C, Morán M, Guillén-Navarro E, Martín MA. A Novel Mutation Associated with Neonatal Lethal Cardiomyopathy Leads to an Alternative Transcript Expression in the X-Linked Complex I NDUFB11 Gene. Int J Mol Sci 2023; 24:ijms24021743. [PMID: 36675256 PMCID: PMC9865986 DOI: 10.3390/ijms24021743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 01/05/2023] [Accepted: 01/11/2023] [Indexed: 01/18/2023] Open
Abstract
We report a neonatal patient with hypertrophic cardiomyopathy (HCM), lactic acidosis and isolated complex I deficiency. Using a customized next-generation sequencing panel, we identified a novel hemizygous variant c.338G>A in the X-linked NDUFB11 gene that encodes the NADH: ubiquinone oxidoreductase subunit B11 of the mitochondrial respiratory chain (MRC) complex I (CI). Molecular and functional assays performed in the proband’s target tissues—skeletal and heart muscle—showed biochemical disturbances of the MRC, suggesting a pathogenic role for this variant. In silico analyses initially predicted an amino acid missense change p.(Arg113Lys) in the NDUFB11 CI subunit. However, we showed that the molecular effect of the c.338G>A variant, which is located at the last nucleotide of exon 2 of the NDUFB11 gene in the canonical ‘short’ transcript (sized 462 bp), instead causes a splicing defect triggering the up-regulation of the expression of an alternative ‘long’ transcript (sized 492 bp) that can also be detected in the control individuals. Our results support the hypothesis that the canonical ‘short’ transcript is required for the proper NDUFB11 protein synthesis, which is essential for optimal CI assembly and activity, whereas the longer alternative transcript seems to represent a non-functional, unprocessed splicing intermediate. Our results highlight the importance of characterizing the molecular effect of new variants in the affected patient’s tissues to demonstrate their pathogenicity and association with the clinical phenotypes.
Collapse
Affiliation(s)
- Guillermo Amate-García
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
| | - María Juliana Ballesta-Martínez
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
- Sección de Genética Médica, Servicio de Pediatría, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB) Pascual Parrilla, 30120 Murcia, Spain
| | - Pablo Serrano-Lorenzo
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Rocío Garrido-Moraga
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
| | - Adrián González-Quintana
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Alberto Blázquez
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Juan C. Rubio
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Inés García-Consuegra
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Joaquín Arenas
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Cristina Ugalde
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - María Morán
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Encarnación Guillén-Navarro
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
- Sección de Genética Médica, Servicio de Pediatría, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB) Pascual Parrilla, 30120 Murcia, Spain
- Facultad de Medicina, Universidad de Murcia, 30120 Murcia, Spain
| | - Miguel A. Martín
- Grupo de Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
- Servicio de Genética, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Correspondence:
| |
Collapse
|
10
|
Ruiz-Muñoz A, Siles JA, Márquez P, Toledo M, Gutiérrez MC, Martín MA. Odor emission assessment of different WWTPs with Extended Aeration Activated Sludge and Rotating Biological Contactor technologies in the province of Cordoba (Spain). J Environ Manage 2023; 326:116741. [PMID: 36399884 DOI: 10.1016/j.jenvman.2022.116741] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 11/04/2022] [Accepted: 11/07/2022] [Indexed: 06/16/2023]
Abstract
In this study, five urban WWTPs (Wastewater Treatment Plant) with different biological treatment (Extended Aeration Activated Sludge - EAAS; Rotating Biological Contactor - RBC), wastewater type (Urban; Industrial) and size, were jointly evaluated. The aim was twofold: (1) to analyze and compare their odor emissions, and (2) to identify the main causes of its generation from the relationships between physico-chemical, respirometric and olfactometric variables. The results showed that facilities with EAAS technology were more efficient than RBC, with elimination yields of organic matter higher than 90%. In olfactometric terms, sludge managements facilities (SMFs) were found to be the critical odor source in all WWTPs compared to the Inlet point (I) or Post primary treatment (PP), and for seasonal periods with ambient temperature higher than 25 °C. Moreover, the global odor emissions quantified in all SMFs revealed that facilities with EAAS (C-WWTP, V-WWTP and Z-WWTP) had a lower odor contribution (19,345, 14,800 and 11,029 ouE/s·m2, respectively) than for those with RBC technology (P-WWTP and NC-WWTP) which accounted for 19,747 ouE/s·m2 and 80,061 ouE/s·m2, respectively. In addition, chemometric analysis helped to find groupings and differences between the WWTPs considering the wastewater (71.27% of total variance explained) and sludge management (64.52% of total variance explained) lines independently. Finally, odor emissions were adequately predicted from the physico-chemical and respirometric variables in the wastewater (r2 = 0.8738) and sludge (r2 = 0.9373) lines, being pH, volatile acidity and temperature (wastewater line), and pH, moisture, temperature, SOUR (Specific Oxygen Uptake Rate) and OD20 (Cumulative Oxygen Demand at 20 h) (sludge line) the most influential variables.
Collapse
Affiliation(s)
- A Ruiz-Muñoz
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Instituto Químico para La Energía y El Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, Edificio Marie Curie, 14071, Córdoba, Spain
| | - J A Siles
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Instituto Químico para La Energía y El Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, Edificio Marie Curie, 14071, Córdoba, Spain
| | - P Márquez
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Instituto Químico para La Energía y El Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, Edificio Marie Curie, 14071, Córdoba, Spain
| | - M Toledo
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Instituto Químico para La Energía y El Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, Edificio Marie Curie, 14071, Córdoba, Spain
| | - M C Gutiérrez
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Instituto Químico para La Energía y El Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, Edificio Marie Curie, 14071, Córdoba, Spain
| | - M A Martín
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Instituto Químico para La Energía y El Medioambiente (IQUEMA), Campus de Excelencia Internacional Agroalimentario ceiA3, Edificio Marie Curie, 14071, Córdoba, Spain.
| |
Collapse
|
11
|
Hamraoui K, Siles JA, Chica AF, Martín MA, El Bari H. Kinetics of combined hydrothermal pretreatment and anaerobic digestion of lignocellulosic biomass (pepper plant and eggplant). Environ Technol 2023; 44:501-511. [PMID: 34469279 DOI: 10.1080/09593330.2021.1976283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 08/17/2021] [Indexed: 06/13/2023]
Abstract
A large quantity of lignocellulosic biomass is generated annually across the world which leads to environmental pollution and requires valorization. This study investigated the effect of hydrothermal pretreatment on the anaerobic digestion and co-digestion of the residual pepper plant and eggplant with a focus on kinetics. Two thermal hydrolysis rates were observed, with the optimal conditions for the hydrothermal pretreatment of lignocellulosic biomass being 120°C for 40 min. Subsequently, single and combined biomethanization was successfully carried out in laboratory-scale completely stirred tank reactors at mesophilic temperature (35°C). A high increase in methane production was observed after the pretreatment of the pepper plant and eggplant. The pretreated and co-digested wastes led to an optimal methane yield of 79 ± 23 mL CH4/g VS. The modified Gompertz model was used to fit the cumulative methane production of the pretreated lignocellulosic substrates. The kinetic model adequately reproduced the experimental results and might be considered a useful tool to simulate the biomethanization behaviour of complex organic substrates.
Collapse
Affiliation(s)
- K Hamraoui
- Faculty of Sciences IbnTofail, Renewable Energy and Environment Laboratory, Kénitra, Morocco
| | - J A Siles
- Department of Inorganic Chemistry and Chemical Engineering, University of Cordoba, Cordoba, Spain
| | - A F Chica
- Department of Inorganic Chemistry and Chemical Engineering, University of Cordoba, Cordoba, Spain
| | - M A Martín
- Department of Inorganic Chemistry and Chemical Engineering, University of Cordoba, Cordoba, Spain
| | - H El Bari
- Faculty of Sciences IbnTofail, Renewable Energy and Environment Laboratory, Kénitra, Morocco
| |
Collapse
|
12
|
Villarreal-Salazar M, Santalla A, Real-Martínez A, Nogales-Gadea G, Valenzuela PL, Fiuza-Luces C, Andreu AL, Rodríguez-Aguilera JC, Martín MA, Arenas J, Vissing J, Lucia A, Krag TO, Pinós T. Low aerobic capacity in McArdle disease: A role for mitochondrial network impairment? Mol Metab 2022; 66:101648. [PMID: 36455789 PMCID: PMC9758572 DOI: 10.1016/j.molmet.2022.101648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 11/14/2022] [Accepted: 11/24/2022] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND McArdle disease is caused by myophosphorylase deficiency and results in complete inability for muscle glycogen breakdown. A hallmark of this condition is muscle oxidation impairment (e.g., low peak oxygen uptake (VO2peak)), a phenomenon traditionally attributed to reduced glycolytic flux and Krebs cycle anaplerosis. Here we hypothesized an additional role for muscle mitochondrial network alterations associated with massive intracellular glycogen accumulation. METHODS We analyzed in depth mitochondrial characteristics-content, biogenesis, ultrastructure-and network integrity in skeletal-muscle from McArdle/control mice and two patients. We also determined VO2peak in patients (both sexes, N = 145) and healthy controls (N = 133). RESULTS Besides corroborating very poor VO2peak values in patients and impairment in muscle glycolytic flux, we found that, in McArdle muscle: (a) damaged fibers are likely those with a higher mitochondrial and glycogen content, which show major disruption of the three main cytoskeleton components-actin microfilaments, microtubules and intermediate filaments-thereby contributing to mitochondrial network disruption in skeletal muscle fibers; (b) there was an altered subcellular localization of mitochondrial fission/fusion proteins and of the sarcoplasmic reticulum protein calsequestrin-with subsequent alteration in mitochondrial dynamics/function; impairment in mitochondrial content/biogenesis; and (c) several OXPHOS-related complex proteins/activities were also affected. CONCLUSIONS In McArdle disease, severe muscle oxidative capacity impairment could also be explained by a disruption of the mitochondrial network, at least in those fibers with a higher capacity for glycogen accumulation. Our findings might pave the way for future research addressing the potential involvement of mitochondrial network alterations in the pathophysiology of other glycogenoses.
Collapse
Affiliation(s)
- M Villarreal-Salazar
- Mitochondrial and Neuromuscular Disorders Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - A Santalla
- Universidad Pablo de Olavide, Sevilla, Spain
| | - A Real-Martínez
- Mitochondrial and Neuromuscular Disorders Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - G Nogales-Gadea
- Grup de Recerca en Malalties Neuromusculars i Neuropediàtriques, Department of Neurosciences, Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol i Campus Can Ruti, Universitat Autònoma de Barcelona, Badalona, Spain
| | - P L Valenzuela
- Physical Activity and Health Research Group ('PaHerg'), Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | - C Fiuza-Luces
- Physical Activity and Health Research Group ('PaHerg'), Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | - A L Andreu
- EATRIS, European Infrastructure for Translational Medicine, Amsterdam, Netherlands
| | - J C Rodríguez-Aguilera
- Universidad Pablo de Olavide, Sevilla, Spain; Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide, Sevilla, Spain
| | - M A Martín
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain; Mitochondrial and Neuromuscular Diseases Laboratory, 12 de Octubre Hospital Research Institute (i+12), Madrid, Spain
| | - J Arenas
- Mitochondrial and Neuromuscular Diseases Laboratory, 12 de Octubre Hospital Research Institute (i+12), Madrid, Spain
| | - J Vissing
- Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - A Lucia
- Faculty of Sport Sciences, European University, Madrid, Spain
| | - T O Krag
- Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
| | - T Pinós
- Mitochondrial and Neuromuscular Disorders Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
| |
Collapse
|
13
|
Fernández-Vizarra E, López-Calcerrada S, Sierra-Magro A, Pérez-Pérez R, Formosa LE, Hock DH, Illescas M, Peñas A, Brischigliaro M, Ding S, Fearnley IM, Tzoulis C, Pitceathly RDS, Arenas J, Martín MA, Stroud DA, Zeviani M, Ryan MT, Ugalde C. Two independent respiratory chains adapt OXPHOS performance to glycolytic switch. Cell Metab 2022; 34:1792-1808.e6. [PMID: 36198313 DOI: 10.1016/j.cmet.2022.09.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 06/21/2022] [Accepted: 09/08/2022] [Indexed: 01/11/2023]
Abstract
The structural and functional organization of the mitochondrial respiratory chain (MRC) remains intensely debated. Here, we show the co-existence of two separate MRC organizations in human cells and postmitotic tissues, C-MRC and S-MRC, defined by the preferential expression of three COX7A subunit isoforms, COX7A1/2 and SCAFI (COX7A2L). COX7A isoforms promote the functional reorganization of distinct co-existing MRC structures to prevent metabolic exhaustion and MRC deficiency. Notably, prevalence of each MRC organization is reversibly regulated by the activation state of the pyruvate dehydrogenase complex (PDC). Under oxidative conditions, the C-MRC is bioenergetically more efficient, whereas the S-MRC preferentially maintains oxidative phosphorylation (OXPHOS) upon metabolic rewiring toward glycolysis. We show a link between the metabolic signatures converging at the PDC and the structural and functional organization of the MRC, challenging the widespread notion of the MRC as a single functional unit and concluding that its structural heterogeneity warrants optimal adaptation to metabolic function.
Collapse
Affiliation(s)
- Erika Fernández-Vizarra
- Medical Research Council, Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK; Veneto Institute of Molecular Medicine, 35129 Padova, Italy; Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy.
| | | | - Ana Sierra-Magro
- Instituto de Investigación Hospital 12 de Octubre, Madrid 28041, Spain
| | | | - Luke E Formosa
- Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, 3800 Melbourne, Australia
| | - Daniella H Hock
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, 3052 Melbourne, Australia
| | - María Illescas
- Instituto de Investigación Hospital 12 de Octubre, Madrid 28041, Spain
| | - Ana Peñas
- Instituto de Investigación Hospital 12 de Octubre, Madrid 28041, Spain
| | | | - Shujing Ding
- Medical Research Council, Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK
| | - Ian M Fearnley
- Medical Research Council, Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK
| | - Charalampos Tzoulis
- Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital and Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway
| | - Robert D S Pitceathly
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK
| | - Joaquín Arenas
- Instituto de Investigación Hospital 12 de Octubre, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain
| | - Miguel A Martín
- Instituto de Investigación Hospital 12 de Octubre, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain
| | - David A Stroud
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, 3052 Melbourne, Australia
| | - Massimo Zeviani
- Medical Research Council, Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK; Veneto Institute of Molecular Medicine, 35129 Padova, Italy; Department of Neurosciences, University of Padova, 35128 Padova, Italy
| | - Michael T Ryan
- Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, 3800 Melbourne, Australia
| | - Cristina Ugalde
- Instituto de Investigación Hospital 12 de Octubre, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| |
Collapse
|
14
|
Serrano-Lorenzo P, Rabasa M, Esteban J, Hidalgo Mayoral I, Domínguez-González C, Blanco-Echevarría A, Garrido-Moraga R, Lucia A, Blázquez A, Rubio JC, Palma-Milla C, Arenas J, Martín MA. Clinical, Biochemical, and Molecular Characterization of Two Families with Novel Mutations in the LDHA Gene (GSD XI). Genes (Basel) 2022; 13:genes13101835. [PMID: 36292720 PMCID: PMC9601687 DOI: 10.3390/genes13101835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 09/30/2022] [Accepted: 10/07/2022] [Indexed: 11/16/2022] Open
Abstract
Lactate dehydrogenase (LDH) catalyzes the reversible conversion of L-lactate to pyruvate. LDH-A deficiency is an autosomal recessive disorder (glycogenosis type XI, OMIM#612933) caused by mutations in the LDHA gene. We present two young adult female patients presenting with intolerance to anaerobic exercise, episodes of rhabdomyolysis, and, in one of the patients, psoriasis-like dermatitis. We identified in the LDHA gene a homozygous c.410C>A substitution that predicts a p.Ser137Ter nonsense mutation in Patient One and a compound heterozygous c.410C>A (p.Ser137Ter) and c.750G>A (p.Trp250Ter) nonsense mutation in Patient Two. The pathogenicity of the variants was demonstrated by electrophoretic separation of LDH isoenzymes. Moreover, a flat lactate curve on the forearm exercise test, along with the clinical combination of myopathy and psoriatic-like dermatitis, can also lead to the diagnosis.
Collapse
Affiliation(s)
- Pablo Serrano-Lorenzo
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - María Rabasa
- Neurology Department, Hospital de Fuenlabrada, 28942 Madrid, Spain
| | - Jesús Esteban
- Neuromuscular Unit, Department of Neurology, 12 de Octubre University Hospital, 28041 Madrid, Spain
| | - Irene Hidalgo Mayoral
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
| | - Cristina Domínguez-González
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | | | - Rocío Garrido-Moraga
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
| | - Alejandro Lucia
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Faculty of Sport Sciences, Universidad Europea de Madrid, 28670 Madrid, Spain
| | - Alberto Blázquez
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
| | - Juan C. Rubio
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
| | - Carmen Palma-Milla
- Department of Genetics, 12 de Octubre University Hospital, 28041 Madrid, Spain
| | - Joaquín Arenas
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
| | - Miguel A. Martín
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain
- Correspondence:
| |
Collapse
|
15
|
Bermejo-Guerrero L, Arteche-López A, de Fuenmayor Fernández de la Hoz C, Hernández-Laín A, Martín MA, Domínguez-González C. A novel MLIP truncating variant in an 80-year-old patient with late-onset progressive weakness. Brain 2022; 145:e99-e102. [PMID: 35915960 DOI: 10.1093/brain/awac286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 07/24/2022] [Indexed: 11/12/2022] Open
Affiliation(s)
- Laura Bermejo-Guerrero
- Neuromuscular Unit, Department of Neurology, 12 de Octubre University Hospital, 28041, Madrid, Spain
| | - Ana Arteche-López
- Department of Genetics, 12 de Octubre University Hospital, 28041, Madrid, Spain.,UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, 28041, Madrid, Spain
| | | | - Aurelio Hernández-Laín
- Neuropathology Unit, Department of Pathology, 12 de Octubre University Hospital, 28041, Madrid, Spain.,imas12 Research Institute, 12 de Octubre University Hospital, 28041, Madrid, Spain
| | - Miguel A Martín
- imas12 Research Institute, 12 de Octubre University Hospital, 28041, Madrid, Spain.,Mitochondrial Disorders Laboratory, Clinical Biochemistry Department. 12 de Octubre University Hospital, 28041, Madrid, Spain.,Biomedical Network Research Center on Rare Diseases (CIBERER), 28029, Madrid, Spain
| | - Cristina Domínguez-González
- Neuromuscular Unit, Department of Neurology, 12 de Octubre University Hospital, 28041, Madrid, Spain.,imas12 Research Institute, 12 de Octubre University Hospital, 28041, Madrid, Spain.,Biomedical Network Research Center on Rare Diseases (CIBERER), 28029, Madrid, Spain
| |
Collapse
|
16
|
Santalla A, Valenzuela PL, Rodriguez-Lopez C, Rodríguez-Gómez I, Nogales-Gadea G, Pinós T, Arenas J, Martín MA, Santos-Lozano A, Morán M, Fiuza-Luces C, Ara I, Lucia A. Long-Term Exercise Intervention in Patients with McArdle Disease: Clinical and Aerobic Fitness Benefits. Med Sci Sports Exerc 2022; 54:1231-1241. [PMID: 35320153 DOI: 10.1249/mss.0000000000002915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
INTRODUCTION The long-term effects of exercise in patients with McArdle disease-the paradigm of "exercise intolerance"-are unknown. This is an important question because the severity of the disease frequently increases with time. PURPOSE This study aimed to study the effects of a long-term exercise intervention on clinical and fitness-related outcomes in McArdle patients. METHODS Seventeen patients (exercise group: n = 10, 6 male, 38 ± 18 yr; control: n = 7, 4 male, 38 ± 18 yr) participated in a 2-yr unsupervised intervention including moderate-intensity aerobic (cycle-ergometer exercise for 1 h) and resistance (high load-low repetition circuit) training on 5 and 2-3 d·wk -1 , respectively. Patients were assessed at baseline and postintervention. Besides safety, outcomes included clinical severity (e.g., exercise intolerance features) on a 0-3 scale (primary outcome), and aerobic fitness, gross muscle efficiency, and body composition (total/regional fat, muscle, and bone mass; secondary outcomes). RESULTS The exercise program was safe and resulted in a reduction of 1 point (-1.0; 95% confidence interval, -1.6 to -0.5; P = 0.025) in clinical severity versus the control group, with 60% of participants in the exercise group becoming virtually asymptomatic and with no functional limitation in daily life activities. Compared with controls, the intervention induced significant and large benefits (all P < 0.05) in the workload eliciting the ventilatory threshold (both in absolute (watts, +37%) and relative units (watts per kilogram of total body mass or of lower-limb muscle mass, +44%)), peak oxygen uptake (in milliliters per kilogram per minute, +28%), and peak workload (in absolute (+27%) and relative units (+33%)). However, no significant changes were found for muscle efficiency or for any measure of body composition. CONCLUSIONS A 2-yr unsupervised intervention including aerobic and resistance exercise is safe and induces major benefits in the clinical course and aerobic fitness of patients with McArdle disease.
Collapse
Affiliation(s)
| | | | | | | | - Gisela Nogales-Gadea
- Neuromuscular and Neuropediatric Research Group, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Campus Can Ruti, Universitat Autònoma de Barcelona, Badalona, SPAIN
| | | | | | | | | | | | - Carmen Fiuza-Luces
- Instituto de Investigación Sanitaria Hospital "12 de Octubre" ("imas12"), Madrid, SPAIN
| | | | | |
Collapse
|
17
|
García-Consuegra I, Asensio-Peña S, Garrido-Moraga R, Pinós T, Domínguez-González C, Santalla A, Nogales-Gadea G, Serrano-Lorenzo P, Andreu AL, Arenas J, Zugaza JL, Lucia A, Martín MA. Identification of Potential Muscle Biomarkers in McArdle Disease: Insights from Muscle Proteome Analysis. Int J Mol Sci 2022; 23:4650. [PMID: 35563042 PMCID: PMC9100117 DOI: 10.3390/ijms23094650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 04/03/2022] [Accepted: 04/18/2022] [Indexed: 02/04/2023] Open
Abstract
Glycogen storage disease type V (GSDV, McArdle disease) is a rare genetic myopathy caused by deficiency of the muscle isoform of glycogen phosphorylase (PYGM). This results in a block in the use of muscle glycogen as an energetic substrate, with subsequent exercise intolerance. The pathobiology of GSDV is still not fully understood, especially with regard to some features such as persistent muscle damage (i.e., even without prior exercise). We aimed at identifying potential muscle protein biomarkers of GSDV by analyzing the muscle proteome and the molecular networks associated with muscle dysfunction in these patients. Muscle biopsies from eight patients and eight healthy controls showing none of the features of McArdle disease, such as frequent contractures and persistent muscle damage, were studied by quantitative protein expression using isobaric tags for relative and absolute quantitation (iTRAQ) followed by artificial neuronal networks (ANNs) and topology analysis. Protein candidate validation was performed by Western blot. Several proteins predominantly involved in the process of muscle contraction and/or calcium homeostasis, such as myosin, sarcoplasmic/endoplasmic reticulum calcium ATPase 1, tropomyosin alpha-1 chain, troponin isoforms, and alpha-actinin-3, showed significantly lower expression levels in the muscle of GSDV patients. These proteins could be potential biomarkers of the persistent muscle damage in the absence of prior exertion reported in GSDV patients. Further studies are needed to elucidate the molecular mechanisms by which PYGM controls the expression of these proteins.
Collapse
Affiliation(s)
- Inés García-Consuegra
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain;
| | - Sara Asensio-Peña
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
| | - Rocío Garrido-Moraga
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
| | - Tomàs Pinós
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain;
- Mitochondrial and Neuromuscular Disorders Unit, Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Cristina Domínguez-González
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain;
| | - Alfredo Santalla
- Department of Computer and Sport Sciences, Universidad Pablo de Olavide, 41013 Sevilla, Spain;
| | - Gisela Nogales-Gadea
- Grup de Recerca en Malalties Neuromusculars i Neuropediàtriques, Department of Neurosciences, Institut d’Investigacio en Ciencies de la Salut Germans Trias i Pujol i Campus Can Ruti, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain;
| | - Pablo Serrano-Lorenzo
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain;
| | - Antoni L. Andreu
- EATRIS, European Infrastructure for Translational Medicine, 1019 Amsterdam, The Netherlands;
| | - Joaquín Arenas
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain;
| | - José L. Zugaza
- Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU, and Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain;
- IKERBASQUE, Basque Foundation for Science, Plaza Euskadi 5, 48009 Bilbao, Spain
| | - Alejandro Lucia
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
- Faculty of Sport Sciences, Universidad Europea de Madrid, 28670 Madrid, Spain
| | - Miguel A. Martín
- Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain; (I.G.-C.); (S.A.-P.); (R.G.-M.); (C.D.-G.); (P.S.-L.); (J.A.); (A.L.)
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain;
| |
Collapse
|
18
|
Guerrero-Molina MP, Morales-Conejo M, Delmiro A, Morán M, Domínguez-González C, Arranz-Canales E, Ramos-González A, Arenas J, Martín MA, González de la Aleja J. Elevated glutamate and decreased glutamine levels in the cerebrospinal fluid of patients with MELAS syndrome. J Neurol 2022; 269:3238-3248. [PMID: 35088140 PMCID: PMC8794606 DOI: 10.1007/s00415-021-10942-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 11/22/2022]
Abstract
Background Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder caused by mitochondrial DNA (mtDNA) mutations in the MT-TL1 gene. The pathophysiology of neurological manifestations is still unclear, but neuronal hyperexcitability and neuron–astrocyte uncoupling have been suggested. Glutamatergic neurotransmission is linked to glucose oxidation and mitochondrial metabolism in astrocytes and neurons. Given the relevance of neuron–astrocyte metabolic coupling and astrocyte function regulating energetic metabolism, we aimed to assess glutamate and glutamine CSF levels in MELAS patients. Methods This prospective observational case–control study determined glutamate and glutamine CSF levels in patients with MELAS syndrome and compared them with controls. The plasma and CSF levels of the remaining amino acids and lactate were also determined. Results Nine adult patients with MELAS syndrome (66.7% females mean age 35.8 ± 3.2 years) and 19 controls (63.2% females mean age 42.7 ± 3.8 years) were included. The CSF glutamate levels were significantly higher in patients with MELAS than in controls (18.48 ± 1.34 vs. 5.31 ± 1.09 μmol/L, p < 0.001). Significantly lower glutamine concentrations in patients with MELAS than controls were shown in CSF (336.31 ± 12.92 vs. 407.06 ± 15.74 μmol/L, p = 0.017). Moreover, the CSF levels of alanine, the branched-chain amino acids (BCAAs) and lactate were significantly higher in patients with MELAS. Conclusions Our results suggest the glutamate–glutamine cycle is altered probably due to metabolic imbalance, and as a result, the lactate–alanine and BCAA–glutamate cycles are upregulated. These findings might have therapeutic implications in MELAS syndrome. Supplementary Information The online version contains supplementary material available at 10.1007/s00415-021-10942-7.
Collapse
Affiliation(s)
- María Paz Guerrero-Molina
- Neuromuscular Disorders Unit, Neurology Department, University Hospital, 12 de Octubre, Madrid, Spain.
| | - Montserrat Morales-Conejo
- Department of Internal Medicine, University Hospital, 12 de Octubre, Madrid, Spain.,National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
| | - Aitor Delmiro
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - María Morán
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Cristina Domínguez-González
- Neuromuscular Disorders Unit, Neurology Department, University Hospital, 12 de Octubre, Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Elena Arranz-Canales
- Department of Internal Medicine, University Hospital, 12 de Octubre, Madrid, Spain.,National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain
| | - Ana Ramos-González
- Department of Neuroradiology, University Hospital, 12 de Octubre, Madrid, Spain
| | - Joaquín Arenas
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Miguel A Martín
- Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.,Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Research Institute ('imas12'), University Hospital, 12 de Octubre, Madrid, Spain
| | - Jesús González de la Aleja
- National Reference Center for Congenital Errors of Metabolism (CSUR) an European Reference Center for Inherited Metabolic Disease (MetabERN), University Hospital, 12 de Octubre, Madrid, Spain.,Epilepsy Unit, Neurology Department, University Hospital, 12 de Octubre, Madrid, Spain
| |
Collapse
|
19
|
Luque J, Mendes I, Gómez B, Morte B, Heredia ML, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Pérez‐Jurado LA, Montoliu L, Carracedo Á, Millán JM, Webb SM, Palau F, Lapunzina P, Aguado C, Aguado C, Albiñana V, Alías L, Almoguera B, Alonso J, Alonso‐Ferreira V, Alvarez‐Mora MI, Alvarez‐Mora MI, Antiñolo G, Arbones ML, Arenas J, Arjona E, Armangue T, Armstrong J, Arnedo M, Artuch R, Masó AA, Avila‐Fernandez A, Ayuso C, Badell I, Badenas C, Baeza ML, Baiget M, Balcells S, Ballesta‐Martínez MJ, Barahona M, Barros F, Bartoccioni PC, Bayona‐Bafaluy MP, Sanz SB, Bernabéu C, Bernal S, Blanco‐Kelly F, Blázquez A, Bodoy S, Bogliolo M, Borralleras C, Borrego S, Botella LM, Pieri FB, Bovolenta P, Bravo‐Gil N, Brea A, Bueno‐Lozano G, Bueren J, Bustamante A, Caballero T, Camacho‐Macorra C, Cámara Y, Camats‐Tarruella N, Barrio ÁC, Campuzano V, Cantarero L, Cantó J, Caparrós‐Martín JA, Cardellach F, Carmona R, Carracedo Á, Carretero M, Casado M, Casado JA, Casasnovas C, Cascón A, Casino P, Castaño L, Castilla‐Vallmanya L, Catala A, Cayuela ML, Cediel R, Cervera J, Codina‐Solà M, Contreras J, Cormand B, Corominas R, Corral J, Corrochano V, Cortés‐Rodríguez A, Corton M, Costa‐Roger M, Cozar M, Crespo I, Crispi F, Cruz R, Cuezva JM, Cuscó I, Dalmau J, Cima S, Luna S, De Luna N, Oyarzabal Sanz A, Campo M, Castillo I, Molina LDP, Pozo ÁD, Río M, Delmiro A, Desviat LR, Dierssen M, Domínguez‐González C, Domínguez‐Ruiz M, Dopazo J, Errasti E, Escámez MJ, Estañ MC, Esteban J, Estévez R, Ezquieta B, Fernández L, Fernández A, Fernández‐Cancio M, Fernàndez‐Castillo N, Jose PF, Fillat C, Fons C, Fort J, Fourcade S, Fraga MF, Gallano P, Gallardo E, García M, García‐Arumí E, García‐Bravo M, García‐Cazorla A, García‐Consuegra I, Garcia‐Garcia FJ, García‐García G, García‐Giménez JL, Garcia‐Gimeno MA, García‐Miñaur S, García‐Redondo A, García‐Silva MT, García‐Villoria J, Santiago FG, Garrabou G, Garrido G, Garrido‐Pérez N, Gaztambide S, Gil‐Campos M, Giroud‐Gerbetant J, Glover G, Gómez B, Gómez‐Puertas P, Gonzalez‐Cabo P, Gonzalez‐Casacuberta I, Pozo MG, González‐Quereda L, González‐Quintana A, Gort L, Gougeard N, Gratacos E, Grau JM, Grinberg D, Güenechea G, Guerrero R, Guillén‐Navarro E, Guitart‐Mampel M, Gutiérrez‐Arumí A, Heath K, Heredia M, Hernández‐Chico C, Herreras E, Hoenicka J, Homs A, Jimenez‐Estrada JA, Jimenez‐Mallebrera C, Jou C, Juarez‐Flores DL, Lapunzina P, Larcher F, Lasa A, Lassaletta L, Latorre‐Pellicer A, Linares D, Llacer JL, Llames S, Lopez‐Gallardo E, López‐Laso E, López‐Lera A, Lopez‐Lopez D, López‐Sánchez M, Heredia ML, Granados EL, Lorda‐Sanchez I, Lozano ML, Luque J, Madrigal I, García CM, Mansilla E, Marco‐Marín C, Marfany G, Marina A, Martí R, Martí S, Martin Y, Martín MA, Martín‐Hernandez E, Martin‐Merida I, Martínez R, Martínez‐Azorín F, Martinez‐Delgado B, Martínez‐Gil N, Martínez‐Glez VM, Martínez‐Momblán MA, Martínez‐Romero MC, Fernández PM, Santamaría LM, Martorell L, Meade P, Meana Á, Medina MÁ, Mendes I, Méndez‐Vidal C, Millán JM, Minguez P, Minguillón J, Mirra S, Molla B, Moltó E, Montero R, Montoliu L, Montoya J, Morán M, Moren C, Moreno M, Moreno JC, Moreno‐Galdó A, Moreno‐Pelayo MÁ, Mori MA, Morin M, Morte B, Mulero V, Muñoz‐Pujol G, Murillas R, Murillo‐Cuesta S, Nascimento A, Navarro S, Navas P, Nevado J, Nicolas A, Nieto MÁ, O’Callaghan M, Olavarrieta L, Ormazabal A, Ortiz‐Romero P, Osorio A, Páez D, Palacín M, Palacios‐Verdú MG, Palau F, Palencia‐Campos A, Pallardó FV, Palomares M, Peña‐Chilet M, Pérez B, Perez‐Florido J, Pérez‐García D, Perez‐Jimenez E, Pérez‐Jurado LA, Perkins JR, Perona R, Pie J, Pinós T, Pinto S, Potrony M, Puig S, Puig‐Butille JA, Puisac B, Pujol R, Pujol A, Quintana Ó, Rabionet R, Ramos FJ, Ranea JAG, Reina‐Castillón J, Resmini E, Ribes A, Rica I, Richard E, Riera P, Río P, Riveiro‐Alvarez R, Rivera J, Rivera‐Barahona A, Robledo M, Rodriguez‐Aguilera JC, Rosa LR, Rodríguez‐Palmero A, Rodriguez‐Pombo P, Rodriguez‐Revenga L, Rodríguez‐Santiago B, Rodríguez‐Sureda V, Alba MR, Cordoba SR, Romá‐Mateo C, Rubio V, Ruiz Á, Ruiz M, Ruiz‐Arenas C, Ruiz‐Perez VL, Ruiz‐Pesini E, Ruiz‐Ponte C, Rullo J, Sabater L, Salazar J, Salido E, Sanchez‐Jimeno C, Cuesta AMS, Soler MJS, Santacatterina F, Santamarina M, Santos A, Santos‐Ocaña C, Simarro FS, Sanz P, Sastre L, Schlüter A, Segovia JC, Segura‐Puimedon M, Seoane P, Serra‐Juhe C, Serrano M, Serratosa JM, Sevilla T, Surrallés J, Tahsin‐Swafiri S, Tell‐Martí G, Tenorio‐Castaño JA, Tizzano E, Tobias E, Tort F, Trujillano L, Trujillo‐Tiebas MJ, Ugalde C, Ugarteburu O, Urreizti R, Urrutia I, Valencia M, Vallcorba P, Vallespín E, Varela‐Nieto I, Vega A, Vélez‐Santamaria V, Vílchez JJ, Villa O, Villamar M, Webb SM, Zubeldia JM, Zurita O. CIBERER: Spanish National Network for Research on Rare Diseases: a highly productive collaborative initiative. Clin Genet 2022; 101:481-493. [PMID: 35060122 PMCID: PMC9305285 DOI: 10.1111/cge.14113] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Revised: 01/13/2022] [Accepted: 01/13/2022] [Indexed: 11/30/2022]
Abstract
CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low‐prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15‐year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research.
Collapse
Affiliation(s)
- Juan Luque
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Ingrid Mendes
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Beatriz Gómez
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Beatriz Morte
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Miguel López Heredia
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Enrique Herreras
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Virginia Corrochano
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Juan Bueren
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS‐FJD), Madrid Spain
| | - Pía Gallano
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Genetics Department, Hospital de la Santa Creu i Sant Pau Barcelona Spain
- Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona Spain
- Universitat Autònoma de Barcelona Barcelona Spain
| | - Rafael Artuch
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Clinical Biochemistry Department, Institut de Recerca Sant Joan de Déu Barcelona Spain
| | - Cristina Fillat
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona Spain
- Universitat de Barcelona Barcelona Spain
| | - Luis A. Pérez‐Jurado
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Experimental and Health Sciences Universitat Pompeu Fabra (UPF), Barcelona Spain
- Genetics Service, Hospital del Mar Barcelona Spain
- Hospital del Mar Research Institute (IMIM), Barcelona Spain
| | - Lluis Montoliu
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Molecular and Cellular Biology, National Centre for Biotechnology (CNB‐CSIC), Madrid Spain
| | - Ángel Carracedo
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Grupo de Medicina Xenómica, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela Santiago de Compostela Spain
- Fundación Pública Galega de Medicina Xenómica (SERGAS), IDIS Santiago de Compostela Spain
| | - José M. Millán
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Unidad de Genética, Hospital Universitario y Politécnico La Fe Valencia Spain
- Biomedicina Molecular Celular y Genómica, Instituto Investigación Sanitaria La Fe Valencia Spain
| | - Susan M. Webb
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Hospital S Pau, Dept Medicine/Endocrinology, IIB‐Sant Pau, Research Center for Pituitary Diseases Barcelona Spain
- Departamento de Medicina Universitat Autònoma de Barcelona Barcelona Spain
| | - Francesc Palau
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Genetic and Molecular Medicine, Hospital Sant Joan de Deu Barcelona Spain
- Laboratory of Neurogenetics and Molecular Medicine ‐ IPER, Institut de Recerca Sant Joan de Déu Barcelona Spain
- Institute of Medicine & Dermatology, Hospital Clínic Barcelona Spain
- Division of Pediatrics University of Barcelona School of Medicine Barcelona Spain
| | - Pablo Lapunzina
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- INGEMM‐Instituto de Genética Médica y Molecular, Hospital Universitario La Paz Madrid Spain
- Instituto de Investigación Sanitaria Hospital La Paz (IdiPAZ), Madrid Spain
- ERN‐ITHACA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Illescas M, Peñas A, Arenas J, Martín MA, Ugalde C. Regulation of Mitochondrial Function by the Actin Cytoskeleton. Front Cell Dev Biol 2022; 9:795838. [PMID: 34993202 PMCID: PMC8725978 DOI: 10.3389/fcell.2021.795838] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Accepted: 12/03/2021] [Indexed: 12/13/2022] Open
Abstract
The regulatory role of actin cytoskeleton on mitochondrial function is a growing research field, but the underlying molecular mechanisms remain poorly understood. Specific actin-binding proteins (ABPs), such as Gelsolin, have also been shown to participate in the pathophysiology of mitochondrial OXPHOS disorders through yet to be defined mechanisms. In this mini-review, we will summarize the experimental evidence supporting the fundamental roles of actin cytoskeleton and ABPs on mitochondrial trafficking, dynamics, biogenesis, metabolism and apoptosis, with a particular focus on Gelsolin involvement in mitochondrial disorders. The functional interplay between the actin cytoskeleton, ABPs and mitochondrial membranes for the regulation of cellular homeostasis thus emerges as a new exciting field for future research and therapeutic approaches.
Collapse
Affiliation(s)
- María Illescas
- Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
| | - Ana Peñas
- Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
| | - Joaquín Arenas
- Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Miguel A Martín
- Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Cristina Ugalde
- Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| |
Collapse
|
21
|
Bermejo-Guerrero L, de Fuenmayor-Fernández de la Hoz CP, Serrano-Lorenzo P, Blázquez-Encinar A, Gutiérrez-Gutiérrez G, Martínez-Vicente L, Galán-Dávila L, García-García J, Arenas J, Muelas N, Hernández-Laín A, Domínguez-González C, Martín MA. Clinical, Histological, and Genetic Features of 25 Patients with Autosomal Dominant Progressive External Ophthalmoplegia (ad-PEO)/PEO-Plus Due to TWNK Mutations. J Clin Med 2021; 11:jcm11010022. [PMID: 35011763 PMCID: PMC8745442 DOI: 10.3390/jcm11010022] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Revised: 12/16/2021] [Accepted: 12/20/2021] [Indexed: 11/28/2022] Open
Abstract
Autosomal dominant mutations in the TWNK gene, which encodes a mitochondrial DNA helicase, cause adult-onset progressive external ophthalmoplegia (PEO) and PEO-plus presentations. In this retrospective observational study, we describe clinical and complementary data from 25 PEO patients with mutations in TWNK recruited from the Hospital 12 de Octubre Mitochondrial Disorders Laboratory Database. The mean ages of onset and diagnosis were 43 and 63 years, respectively. Family history was positive in 22 patients. Ptosis and PEO (92% and 80%) were the most common findings. Weakness was present in 48%, affecting proximal limbs, neck, and bulbar muscles. Exercise intolerance was present in 28%. Less frequent manifestations were cardiac (24%) and respiratory (4%) involvement, neuropathy (8%), ataxia (4%), and parkinsonism (4%). Only 28% had mild hyperCKemia. All 19 available muscle biopsies showed signs of mitochondrial dysfunction. Ten different TWNK mutations were identified, with c.1361T>G (p.Val454Gly) and c.1070G>C (p.Arg357Pro) being the most common. Before definitive genetic confirmation, 56% of patients were misdiagnosed (36% with myasthenia, 20% with oculopharyngeal muscle dystrophy). Accurate differential diagnosis and early confirmation with appropriately chosen complementary studies allow genetic counseling and the avoidance of unnecessary treatments. Thus, mitochondrial myopathies must be considered in PEO/PEO-plus presentations, and particularly, TWNK is an important cause when positive family history is present.
Collapse
Affiliation(s)
- Laura Bermejo-Guerrero
- Neuromuscular Unit, Department of Neurology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain; (L.B.-G.); (C.P.d.F.-F.d.l.H.)
| | | | - Pablo Serrano-Lorenzo
- Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; (P.S.-L.); (A.B.-E.); (J.A.); (A.H.-L.); (M.A.M.)
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | - Alberto Blázquez-Encinar
- Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; (P.S.-L.); (A.B.-E.); (J.A.); (A.H.-L.); (M.A.M.)
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | | | - Laura Martínez-Vicente
- Department of Neurology, Hospital Universitario Clínico San Carlos, 28040 Madrid, Spain; (L.M.-V.); (L.G.-D.)
| | - Lucía Galán-Dávila
- Department of Neurology, Hospital Universitario Clínico San Carlos, 28040 Madrid, Spain; (L.M.-V.); (L.G.-D.)
| | - Jorge García-García
- Department of Neurology, Complejo Hospitalario Universitario de Albacete, 02006 Albacete, Spain;
| | - Joaquín Arenas
- Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; (P.S.-L.); (A.B.-E.); (J.A.); (A.H.-L.); (M.A.M.)
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | - Nuria Muelas
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Neuromuscular Unit, Department of Neurology, Hospital Universitari I Politècnic La Fe, 46026 Valencia, Spain
- Neuromuscular and Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain
| | - Aurelio Hernández-Laín
- Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; (P.S.-L.); (A.B.-E.); (J.A.); (A.H.-L.); (M.A.M.)
- Department of Neuropathology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| | - Cristina Domínguez-González
- Neuromuscular Unit, Department of Neurology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain; (L.B.-G.); (C.P.d.F.-F.d.l.H.)
- Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; (P.S.-L.); (A.B.-E.); (J.A.); (A.H.-L.); (M.A.M.)
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Correspondence:
| | - Miguel A. Martín
- Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; (P.S.-L.); (A.B.-E.); (J.A.); (A.H.-L.); (M.A.M.)
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
| |
Collapse
|
22
|
Bellusci M, Paredes-Fuentes AJ, Ruiz-Pesini E, Gómez B, Martín MA, Montoya J, Artuch R. The Genetic Landscape of Mitochondrial Diseases in Spain: A Nationwide Call. Genes (Basel) 2021; 12:genes12101590. [PMID: 34680984 PMCID: PMC8535857 DOI: 10.3390/genes12101590] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 09/30/2021] [Accepted: 10/05/2021] [Indexed: 01/21/2023] Open
Abstract
The frequency of mitochondrial diseases (MD) has been scarcely documented, and only a few studies have reported data in certain specific geographical areas. In this study, we arranged a nationwide call in Spain to obtain a global estimate of the number of cases. A total of 3274 cases from 49 Spanish provinces were reported by 39 centres. Excluding duplicated and unsolved cases, 2761 patients harbouring pathogenic mutations in 140 genes were recruited between 1990 and 2020. A total of 508 patients exhibited mutations in nuclear DNA genes (75% paediatric patients) and 1105 in mitochondrial DNA genes (33% paediatric patients). A further 1148 cases harboured mutations in the MT-RNR1 gene (56% paediatric patients). The number of reported cases secondary to nuclear DNA mutations increased in 2014, owing to the implementation of next-generation sequencing technologies. Between 2014 and 2020, excepting MT-RNR1 cases, the incidence was 6.34 (95% CI: 5.71–6.97) cases per million inhabitants at the paediatric age and 1.36 (95% CI: 1.22–1.50) for adults. In conclusion, this is the first study to report nationwide epidemiological data for MD in Spain. The lack of identification of a remarkable number of mitochondrial genes necessitates the systematic application of high-throughput technologies in the routine diagnosis of MD.
Collapse
Affiliation(s)
- Marcello Bellusci
- Reference Centre for Inherited Metabolic Disorders, 12 de Octubre University Hospital, 28041 Madrid, Spain;
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain; (E.R.-P.); (B.G.)
| | - Abraham J Paredes-Fuentes
- Clinical Biochemistry Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Esplugues de Llobregat, 08950 Barcelona, Spain;
| | - Eduardo Ruiz-Pesini
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain; (E.R.-P.); (B.G.)
- Department of Biochemistry and Molecular Biology, Institute for Health Research of Aragón (IISAragón), University of Zaragoza, 50009 Zaragoza, Spain
| | - Beatriz Gómez
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain; (E.R.-P.); (B.G.)
| | | | - Miguel A Martín
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain; (E.R.-P.); (B.G.)
- Mitochondrial & Neuromuscular Disorders Laboratory, Instituto de Investigación Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain
- Correspondence: (M.A.M.); (J.M.); (R.A.)
| | - Julio Montoya
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain; (E.R.-P.); (B.G.)
- Department of Biochemistry and Molecular Biology, Institute for Health Research of Aragón (IISAragón), University of Zaragoza, 50009 Zaragoza, Spain
- Correspondence: (M.A.M.); (J.M.); (R.A.)
| | - Rafael Artuch
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain; (E.R.-P.); (B.G.)
- Clinical Biochemistry Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Esplugues de Llobregat, 08950 Barcelona, Spain;
- Correspondence: (M.A.M.); (J.M.); (R.A.)
| |
Collapse
|
23
|
Domínguez-González C, Madruga-Garrido M, Hirano M, Martí I, Martín MA, Munell F, Nascimento A, Olivé M, Quan J, Sardina MD, Martí R, Paradas C. Collaborative model for diagnosis and treatment of very rare diseases: experience in Spain with thymidine kinase 2 deficiency. Orphanet J Rare Dis 2021; 16:407. [PMID: 34600563 PMCID: PMC8487573 DOI: 10.1186/s13023-021-02030-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 09/18/2021] [Indexed: 11/22/2022] Open
Abstract
Background Mitochondrial diseases are difficult to diagnose and treat. Recent advances in genetic diagnostics and more effective treatment options can improve patient diagnosis and prognosis, but patients with mitochondrial disease typically experience delays in diagnosis and treatment. Here, we describe a unique collaborative practice model among physicians and scientists in Spain focused on identifying TK2 deficiency (TK2d), an ultra-rare mitochondrial DNA depletion and deletions syndrome.
Main Body This collaboration spans research and clinical care, including laboratory scientists, adult and pediatric neuromuscular clinicians, geneticists, and pathologists, and has resulted in diagnosis and consolidation of care for patients with TK2d. The incidence of TK2d is not known; however, the first clinical cases of TK2d were reported in 2001, and only ~ 107 unique cases had been reported as of 2018. This unique collaboration in Spain has led to the diagnosis of more than 30 patients with genetically confirmed TK2d across different regions of the country. Research affiliate centers have led investigative treatment with nucleosides based on understanding of TK2d clinical manifestations and disease mechanisms, which resulted in successful treatment of a TK2d mouse model with nucleotide therapy in 2010. Only 1 year later, this collaboration enabled rapid adoption of treatment with pyrimidine nucleotides (and later, nucleosides) under compassionate use. Success in TK2d diagnosis and treatment in Spain is attributable to two important factors: Spain’s fully public national healthcare system, and the designation in 2015 of major National Reference Centers for Neuromuscular Disorders (CSURs). CSUR networking and dissemination facilitated development of a collaborative care network for TK2d disease, wherein participants share information and protocols to request approval from the Ministry of Health to initiate nucleoside therapy. Data have recently been collected in a retrospective study conducted under a Good Clinical Practice–compliant protocol to support development of a new therapeutic approach for TK2d, a progressive disease with no approved therapies. Conclusions The Spanish experience in diagnosis and treatment of TK2d is a model for the diagnosis and development of new treatments for very rare diseases within an existing healthcare system.
Collapse
Affiliation(s)
- Cristina Domínguez-González
- Neuromuscular Disorders Unit, Neurology Department, Hospital 12 de Octubre, Madrid, Spain.,Instituto de Investigación imas12, Hospital 12 de Octubre, Madrid, Spain.,Center for Biomedical Network Research On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Michio Hirano
- Neurology Department, H. Houston Merritt Center, Columbia University Irving Medical Center, New York, NY, USA
| | - Itxaso Martí
- Pediatric Department, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country, San Sebastián, Spain
| | - Miguel A Martín
- Center for Biomedical Network Research On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.,Mitochondrial Diseases Laboratory, Department of Biochemistry, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Francina Munell
- Pediatric Department, Vall d'Hebron Hospital, Barcelona, Spain
| | - Andrés Nascimento
- Center for Biomedical Network Research On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.,Pediatric Department, Vall d'Hebron Hospital, Barcelona, Spain.,Neuromuscular Unit, Neurology Department, Sant Joan de Déu Research Institute, Sant Joan de Déu Hospital, Barcelona, Spain
| | - Montse Olivé
- Neuromuscular Disorders Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau/Center for Biomedical Network Research On Rare Diseases (CIBERER), Barcelona, Spain
| | | | - M Dolores Sardina
- Pediatric Neurology Department, Badajoz Hospital Complex, Badajoz, Spain
| | - Ramon Martí
- Center for Biomedical Network Research On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.,Research Group On Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain
| | - Carmen Paradas
- Neurology Department, Neuromuscular Disorders Unit, Instituto de Biomedicina de Sevilla, Hospital U. Virgen del Rocío, CSIC, Universidad de Sevilla, Avd. Manuel Siurot s/n, 41013, Sevilla, Spain. .,Center for Biomedical Network Research On Neurodegenerative Disorders (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
24
|
Márquez P, Herruzo-Ruiz AM, Siles JA, Alhama J, Michán C, Martín MA. Influence of packing material on the biofiltration of butyric acid: A comparative study from a physico-chemical, olfactometric and microbiological perspective. J Environ Manage 2021; 294:113044. [PMID: 34130131 DOI: 10.1016/j.jenvman.2021.113044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 05/10/2021] [Accepted: 06/07/2021] [Indexed: 06/12/2023]
Abstract
The influence of bed material on the odor removal performance of a biofilter was studied. A compost-wood biofilter and a wood biofilter were treated with a gaseous stream contaminated with butyric acid and comparatively evaluated at pilot scale using olfactometric, physico-chemical and microbiological approaches. The variables analyzed in both biofilters were correlated with specific families of their microbiota composition. In addition to a higher nutrients content (nitrogen and phosphorus), the compost-wood biofilter registered maximum values in number of aerobic microorganisms (3.6·108 CFU/g) and in aerobic microbiological activity (≈40 mg O2/g VS of cumulative oxygen demand at 20 h). This may explain the higher performance of this biofilter compared to the wood biofilter, withstanding odor loads of up to 1450 ouE/m2·s with odor removal efficiencies close to 100%. The analysis of the microbial community showed that Actinobacteria, particularly the mostly aerobic Microbacteriaceae family, might play an important role in butyric acid degradation and hence reduce odor impact. The multidisciplinary analysis carried out in this work could be a very useful strategy for the optimal design of biofiltration operations.
Collapse
Affiliation(s)
- P Márquez
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - A M Herruzo-Ruiz
- Department of Biochemistry and Molecular Biology, Universidad de Córdoba, Campus de Excelencia Internacional Agroalimentario CeiA3, Edificio Severo Ochoa, 14071, Córdoba, Spain
| | - J A Siles
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - J Alhama
- Department of Biochemistry and Molecular Biology, Universidad de Córdoba, Campus de Excelencia Internacional Agroalimentario CeiA3, Edificio Severo Ochoa, 14071, Córdoba, Spain
| | - C Michán
- Department of Biochemistry and Molecular Biology, Universidad de Córdoba, Campus de Excelencia Internacional Agroalimentario CeiA3, Edificio Severo Ochoa, 14071, Córdoba, Spain
| | - M A Martín
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, Universidad de Córdoba, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain.
| |
Collapse
|
25
|
Jericó D, Córdoba KM, Jiang L, Schmitt C, Morán M, Sampedro A, Alegre M, Collantes M, Santamaría E, Alegre E, Culerier C, de Mendoza AEH, Oyarzabal J, Martín MA, Peñuelas I, Ávila MA, Gouya L, Martini PGV, Fontanellas A. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks. Mol Ther Nucleic Acids 2021; 25:207-219. [PMID: 34458006 PMCID: PMC8368795 DOI: 10.1016/j.omtn.2021.05.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/12/2020] [Accepted: 05/13/2021] [Indexed: 11/28/2022]
Abstract
Variegate porphyria (VP) results from haploinsufficiency of protoporphyrinogen oxidase (PPOX), the seventh enzyme in the heme synthesis pathway. There is no VP model that recapitulates the clinical manifestations of acute attacks. Combined administrations of 2-allyl-2-isopropylacetamide and rifampicin in rabbits halved hepatic PPOX activity, resulting in increased accumulation of a potentially neurotoxic heme precursor, lipid peroxidation, inflammation, and hepatocyte cytoplasmic stress. Rabbits also showed hypertension, motor impairment, reduced activity of critical mitochondrial hemoprotein functions, and altered glucose homeostasis. Hemin treatment only resulted in a slight drop in heme precursor accumulation but further increased hepatic heme catabolism, inflammation, and cytoplasmic stress. Hemin replenishment did protect against hypertension, but it failed to restore action potentials in the sciatic nerve or glucose homeostasis. Systemic porphobilinogen deaminase (PBGD) mRNA administration increased hepatic PBGD activity, the third enzyme of the pathway, and rapidly normalized serum and urine porphyrin precursor levels. All features studied were improved, including those related to critical hemoprotein functions. In conclusion, the VP model recapitulates the biochemical characteristics and some clinical manifestations associated with severe acute attacks in humans. Systemic PBGD mRNA provided successful protection against the acute attack, indicating that PBGD, and not PPOX, was the critical enzyme for hepatic heme synthesis in VP rabbits.
Collapse
Affiliation(s)
- Daniel Jericó
- Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain
| | - Karol M Córdoba
- Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain
| | - Lei Jiang
- Moderna Inc., Cambridge, MA 02139, USA
| | - Caroline Schmitt
- Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale U1149, 75018 Paris, France.,Centre Français des Porphyries, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris, Colombes et Université de Paris, 92701 Colombes, France
| | - María Morán
- Mitochondrial Diseases Laboratory, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Ana Sampedro
- Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain
| | - Manuel Alegre
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.,Department of Clinical Neurophysiology, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain
| | - María Collantes
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.,MicroPET Research Unit, CIMA-CUN, 31008 Pamplona, Spain.,Nuclear Medicine Department, CUN, 31008 Pamplona, Spain
| | - Eva Santamaría
- Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain
| | - Estíbaliz Alegre
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.,Department of Biochemistry, Service of Biochemistry, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain
| | - Corinne Culerier
- Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale U1149, 75018 Paris, France.,Centre Français des Porphyries, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris, Colombes et Université de Paris, 92701 Colombes, France
| | | | - Julen Oyarzabal
- Small Molecule Discovery Platform, Molecular Therapeutics Program, CIMA-University of Navarra, 31008 Pamplona, Spain
| | - Miguel A Martín
- Mitochondrial Diseases Laboratory, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Iván Peñuelas
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.,MicroPET Research Unit, CIMA-CUN, 31008 Pamplona, Spain.,Nuclear Medicine Department, CUN, 31008 Pamplona, Spain
| | - Matías A Ávila
- Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Laurent Gouya
- Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale U1149, 75018 Paris, France.,Centre Français des Porphyries, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris, Colombes et Université de Paris, 92701 Colombes, France
| | | | - Antonio Fontanellas
- Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain
| |
Collapse
|
26
|
Hungría J, Siles JA, Chica AF, Gil A, Martín MA. Anaerobic co-digestion of winery waste: comparative assessment of grape marc waste and lees derived from organic crops. Environ Technol 2021; 42:3618-3626. [PMID: 32114938 DOI: 10.1080/09593330.2020.1737735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Accepted: 02/24/2020] [Indexed: 06/10/2023]
Abstract
Grapes are one the world's leading fruit crops, with close to 77 million tonnes harvested per year. Grapes are commonly used to produce wine; a process which generates different wastes such as grape mark waste (skins, seeds and stalks), lees and other residues. This study evaluates the treatment of winery waste derived from ecological cultivation by anaerobic digestion to produce energy in the form of methane. Grape marc waste, Verdejo and Pedro Ximenez (PX) wine lees were digested under stable conditions at mesophilic conditions. The PX lees showed the highest methane yield production (433 LSTP CH4/kg VS) with a maximum OLR of 4.58 kg VS/m3·d. In the evaluated range the process was stable with a range of biodegradability of 51-79%. Due to different types of winery waste are generated at consecutive stages of the main production process, the sequential treatment of PX lees, Verdejo lees and grape marc waste in the same anaerobic digester could be an interesting option. This procedure would facilitate the management of the residual streams generated in wineries during the year and promotes the circular economy in the Montilla-Moriles Protected Designation of Origin.
Collapse
Affiliation(s)
- J Hungría
- Department of Chemical Engineering, University of Córdoba, Córdoba, Spain
| | - J A Siles
- Department of Chemical Engineering, University of Córdoba, Córdoba, Spain
| | - A F Chica
- Department of Chemical Engineering, University of Córdoba, Córdoba, Spain
| | - A Gil
- Department of Chemical Engineering, University of Córdoba, Córdoba, Spain
| | - M A Martín
- Department of Chemical Engineering, University of Córdoba, Córdoba, Spain
| |
Collapse
|
27
|
Argüelles R, Toledo M, Martín MA. Study of the Tagus River and Entrepeñas reservoir ecosystem around the Trillo nuclear power plant using chemometric analysis: Influence on water, sediments, algae and fish. Chemosphere 2021; 279:130532. [PMID: 33857647 DOI: 10.1016/j.chemosphere.2021.130532] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 03/15/2021] [Accepted: 04/05/2021] [Indexed: 06/12/2023]
Abstract
The fluvial and aquatic ecosystem of the Tagus River and Entrepeñas reservoir located in the surrounding of the Trillo nuclear power plant (NPP) was evaluated from 1992 to 2008, considering the physical-chemical characteristics, metal content and radiological activity of the water, sediments, algae and fish. The water of both basins demonstrated pH, conductivity, COD, NO3- and DO values within a range considered as good quality and the water quality index (WQI) was found to be within a range of 71-90. Chemometric analysis revealed a shift in the river water (from upstream to downstream) affected by the concentration of salts and metals of natural origin, such as Fe and Al, and slight variations in temperature and radiological activity were detected due to the discharges from the NPP. The hydric conditions contributed to increase or decrease the metal concentration of the river water, the reservoir sediments, algae and fish. Fe and Al were found in higher concentration during drought periods and accumulated in sediments, algae and fish along the river course (from SP1 to SP3). Natural and artificial radionuclides found were 40K with an average of 245 Bq/kg in river sediments, 499 Bq/kg in reservoir sediments and 121 Bq/kg in fish, and 90Sr with a concentration between 0.40 and 1.30 Bq/kg in sediments. Contamination of the aquatic ecosystem with metals and radionuclides was low according to European legislation. In conclusion, this study provides additional elements aimed at understanding the dynamics of fluvial and lentic ecosystems under the influence of different disturbances.
Collapse
Affiliation(s)
- R Argüelles
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - M Toledo
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - M A Martín
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain.
| |
Collapse
|
28
|
Fernández-Vizarra E, López-Calcerrada S, Formosa LE, Pérez-Pérez R, Ding S, Fearnley IM, Arenas J, Martín MA, Zeviani M, Ryan MT, Ugalde C. SILAC-based complexome profiling dissects the structural organization of the human respiratory supercomplexes in SCAFI KO cells. Biochim Biophys Acta Bioenerg 2021; 1862:148414. [PMID: 33727070 DOI: 10.1016/j.bbabio.2021.148414] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 03/09/2021] [Accepted: 03/10/2021] [Indexed: 12/29/2022]
Abstract
The study of the mitochondrial respiratory chain (MRC) function in relation with its structural organization is of great interest due to the central role of this system in eukaryotic cell metabolism. The complexome profiling technique has provided invaluable information for our understanding of the composition and assembly of the individual MRC complexes, and also of their association into larger supercomplexes (SCs) and respirasomes. The formation of the SCs has been highly debated, and their assembly and regulation mechanisms are still unclear. Previous studies demonstrated a prominent role for COX7A2L (SCAFI) as a structural protein bridging the association of individual MRC complexes III and IV in the minor SC III2 + IV, although its relevance for respirasome formation and function remains controversial. In this work, we have used SILAC-based complexome profiling to dissect the structural organization of the human MRC in HEK293T cells depleted of SCAFI (SCAFIKO) by CRISPR-Cas9 genome editing. SCAFI ablation led to a preferential loss of SC III2 + IV and of a minor subset of respirasomes without affecting OXPHOS function. Our data suggest that the loss of SCAFI-dependent respirasomes in SCAFIKO cells is mainly due to alterations on early stages of CI assembly, without impacting the biogenesis of complexes III and IV. Contrary to the idea of SCAFI being the main player in respirasome formation, SILAC-complexome profiling showed that, in wild-type cells, the majority of respirasomes (ca. 70%) contained COX7A2 and that these species were present at roughly the same levels when SCAFI was knocked-out. We thus demonstrate the co-existence of structurally distinct respirasomes defined by the preferential binding of complex IV via COX7A2, rather than SCAFI, in human cultured cells.
Collapse
Affiliation(s)
- Erika Fernández-Vizarra
- Medical Research Council - Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK; Institute of Molecular Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, University Avenue, Glasgow G12 8QQ, Scotland, UK
| | | | - Luke E Formosa
- Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, 3800 Melbourne, Australia
| | - Rafael Pérez-Pérez
- Instituto de Investigación, Hospital Universitario, 12 de Octubre, Madrid 28041, Spain
| | - Shujing Ding
- Medical Research Council - Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK
| | - Ian M Fearnley
- Medical Research Council - Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK
| | - Joaquín Arenas
- Instituto de Investigación, Hospital Universitario, 12 de Octubre, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain
| | - Miguel A Martín
- Instituto de Investigación, Hospital Universitario, 12 de Octubre, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain
| | - Massimo Zeviani
- Medical Research Council - Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK; Department of Neurosciences, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
| | - Michael T Ryan
- Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, 3800 Melbourne, Australia
| | - Cristina Ugalde
- Instituto de Investigación, Hospital Universitario, 12 de Octubre, Madrid 28041, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723 Madrid, Spain.
| |
Collapse
|
29
|
Sánchez-Tejerina D, Panadés-de Oliveira L, Martín MA, Álvarez-Mora MI, Hernández-Lain A, Domínguez-González C. Pearls & Oy-sters: Hickam's Dictum in Genetic Myopathies: When a Proven Pathogenic Mutation Does Not Explain the Phenotype. Neurology 2021; 96:1007-1009. [PMID: 33837115 DOI: 10.1212/wnl.0000000000012000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Daniel Sánchez-Tejerina
- From the Neuromuscular Disorders Unit (C.D.-G.), Department of Neurology (D.S.-T., L.P., C.D.-G.), Laboratory of Mitochondrial Diseases, Department of Biochemistry, Instituto de Investigación (M.A.M.), and Departments of Clinical Genetics (M.I.Á.-M.) and Pathology (Neuropathology) (A.H.-L.), Hospital Universitario 12 de Octubre; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (M.A.M., C.D.-G.), Instituto de Salud Carlos III, Madrid; Department of Biochemistry and Molecular Genetics (M.I.Á.-M.), Hospital Clínic of Barcelona; and Hospital 12 de Octubre Research Institute (imas12) (C.D.-G.), Madrid, Spain
| | - Luísa Panadés-de Oliveira
- From the Neuromuscular Disorders Unit (C.D.-G.), Department of Neurology (D.S.-T., L.P., C.D.-G.), Laboratory of Mitochondrial Diseases, Department of Biochemistry, Instituto de Investigación (M.A.M.), and Departments of Clinical Genetics (M.I.Á.-M.) and Pathology (Neuropathology) (A.H.-L.), Hospital Universitario 12 de Octubre; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (M.A.M., C.D.-G.), Instituto de Salud Carlos III, Madrid; Department of Biochemistry and Molecular Genetics (M.I.Á.-M.), Hospital Clínic of Barcelona; and Hospital 12 de Octubre Research Institute (imas12) (C.D.-G.), Madrid, Spain.
| | - Miguel A Martín
- From the Neuromuscular Disorders Unit (C.D.-G.), Department of Neurology (D.S.-T., L.P., C.D.-G.), Laboratory of Mitochondrial Diseases, Department of Biochemistry, Instituto de Investigación (M.A.M.), and Departments of Clinical Genetics (M.I.Á.-M.) and Pathology (Neuropathology) (A.H.-L.), Hospital Universitario 12 de Octubre; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (M.A.M., C.D.-G.), Instituto de Salud Carlos III, Madrid; Department of Biochemistry and Molecular Genetics (M.I.Á.-M.), Hospital Clínic of Barcelona; and Hospital 12 de Octubre Research Institute (imas12) (C.D.-G.), Madrid, Spain
| | - María I Álvarez-Mora
- From the Neuromuscular Disorders Unit (C.D.-G.), Department of Neurology (D.S.-T., L.P., C.D.-G.), Laboratory of Mitochondrial Diseases, Department of Biochemistry, Instituto de Investigación (M.A.M.), and Departments of Clinical Genetics (M.I.Á.-M.) and Pathology (Neuropathology) (A.H.-L.), Hospital Universitario 12 de Octubre; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (M.A.M., C.D.-G.), Instituto de Salud Carlos III, Madrid; Department of Biochemistry and Molecular Genetics (M.I.Á.-M.), Hospital Clínic of Barcelona; and Hospital 12 de Octubre Research Institute (imas12) (C.D.-G.), Madrid, Spain
| | - Aurelio Hernández-Lain
- From the Neuromuscular Disorders Unit (C.D.-G.), Department of Neurology (D.S.-T., L.P., C.D.-G.), Laboratory of Mitochondrial Diseases, Department of Biochemistry, Instituto de Investigación (M.A.M.), and Departments of Clinical Genetics (M.I.Á.-M.) and Pathology (Neuropathology) (A.H.-L.), Hospital Universitario 12 de Octubre; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (M.A.M., C.D.-G.), Instituto de Salud Carlos III, Madrid; Department of Biochemistry and Molecular Genetics (M.I.Á.-M.), Hospital Clínic of Barcelona; and Hospital 12 de Octubre Research Institute (imas12) (C.D.-G.), Madrid, Spain
| | - Cristina Domínguez-González
- From the Neuromuscular Disorders Unit (C.D.-G.), Department of Neurology (D.S.-T., L.P., C.D.-G.), Laboratory of Mitochondrial Diseases, Department of Biochemistry, Instituto de Investigación (M.A.M.), and Departments of Clinical Genetics (M.I.Á.-M.) and Pathology (Neuropathology) (A.H.-L.), Hospital Universitario 12 de Octubre; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (M.A.M., C.D.-G.), Instituto de Salud Carlos III, Madrid; Department of Biochemistry and Molecular Genetics (M.I.Á.-M.), Hospital Clínic of Barcelona; and Hospital 12 de Octubre Research Institute (imas12) (C.D.-G.), Madrid, Spain
| |
Collapse
|
30
|
Eguiburu-Jaime JL, Delmiro A, Lalueza A, Valenzuela PL, Aguado JM, Lumbreras C, Arenas J, Martín MA, Lucia A, López-Jiménez EA. Soluble fms-like tyrosine kinase-1: a potential early predictor of respiratory failure in COVID-19 patients. Clin Chem Lab Med 2021; 59:e289-e292. [PMID: 33606924 DOI: 10.1515/cclm-2021-0126] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 02/04/2021] [Indexed: 11/15/2022]
Affiliation(s)
| | - Aitor Delmiro
- Clinical Biochemistry Department, Hospital 12 de Octubre, Madrid, Spain
| | - Antonio Lalueza
- Internal Medicine Department, Hospital 12 de Octubre, Madrid, Spain
- Department of Medicine, School of Medicine, Complutense University, Madrid, Spain
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | | | - José M Aguado
- Department of Medicine, School of Medicine, Complutense University, Madrid, Spain
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
- Infectious Diseases Unit, University Hospital 12 de Octubre, Madrid, Spain
| | - Carlos Lumbreras
- Internal Medicine Department, Hospital 12 de Octubre, Madrid, Spain
- Department of Medicine, School of Medicine, Complutense University, Madrid, Spain
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | - Joaquín Arenas
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | - Miguel A Martín
- Clinical Biochemistry Department, Hospital 12 de Octubre, Madrid, Spain
- Infectious Diseases Unit, University Hospital 12 de Octubre, Madrid, Spain
| | - Alejandro Lucia
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
- Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain
| | | |
Collapse
|
31
|
Márquez P, Benítez A, Caballero Á, Siles JA, Martín MA. Integral evaluation of granular activated carbon at four stages of a full-scale WWTP deodorization system. Sci Total Environ 2021; 754:142237. [PMID: 33254922 DOI: 10.1016/j.scitotenv.2020.142237] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 09/02/2020] [Accepted: 09/04/2020] [Indexed: 06/12/2023]
Abstract
Odor emissions from wastewater treatment plants (WWTPs) have always been a public concern. In this work, the physico-chemical, olfactometric and textural characterization of granular active carbon (GAC) used by an urban WWTP as a deodorization system, as well as the chromatographic quantification of the retained odoriferous compounds, have been carried out. These techniques have allowed an integral evaluation of the contaminated GAC and the characterization of the retained gaseous emission from four different stages of the wastewater treatment (pretreatment header: GAC-1; sand and fat removal: GAC-2; sludge thickening: GAC-3; sludge dehydration: GAC-4). A larger amount and variety of retained odoriferous compounds were found in GAC samples from the wastewater line deodorization (GAC-1 and GAC-2) after the same operation time (one year), GAC-1 being the adsorbent bed that retained the highest mass of volatile compounds (approximately 150μg/g GAC). Furthermore, some variables such as the removed specific odor concentration and free micropore volume were inversely correlated (R2=0.9945). The analysis of odor contribution showed that sulfur-containing compounds were the major odor contributors (61-97%). However, hydrogen sulfide cannot be considered a key odorant in this particular WWTP, since the elimination of this compound does not reduce the significant contribution of other (organic) sulfur compounds to the global odor (especially dimethyl disulfide). Consequently, multi-technical analysis might be a suitable alternative to better understand odor removal by GAC adsorption.
Collapse
Affiliation(s)
- P Márquez
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - A Benítez
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Universitario de Nanoquímica, Universidad de Córdoba, 14071 Córdoba, Spain
| | - Á Caballero
- Dpto. Química Inorgánica e Ingeniería Química, Instituto Universitario de Nanoquímica, Universidad de Córdoba, 14071 Córdoba, Spain
| | - J A Siles
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - M A Martín
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain.
| |
Collapse
|
32
|
Fernández-de la Torre M, Fiuza-Luces C, Valenzuela PL, Laine-Menéndez S, Arenas J, Martín MA, Turnbull DM, Lucia A, Morán M. Exercise Training and Neurodegeneration in Mitochondrial Disorders: Insights From the Harlequin Mouse. Front Physiol 2020; 11:594223. [PMID: 33363476 PMCID: PMC7752860 DOI: 10.3389/fphys.2020.594223] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Accepted: 11/10/2020] [Indexed: 01/28/2023] Open
Abstract
Aim Cerebellar neurodegeneration is a main phenotypic manifestation of mitochondrial disorders caused by apoptosis-inducing factor (AIF) deficiency. We assessed the effects of an exercise training intervention at the cerebellum and brain level in a mouse model (Harlequin, Hq) of AIF deficiency. Methods Male wild-type (WT) and Hq mice were assigned to an exercise (Ex) or control (sedentary [Sed]) group (n = 10-12/group). The intervention (aerobic and resistance exercises) was initiated upon the first symptoms of ataxia in Hq mice (∼3 months on average) and lasted 8 weeks. Histological and biochemical analyses of the cerebellum were performed at the end of the training program to assess indicators of mitochondrial deficiency, neuronal death, oxidative stress and neuroinflammation. In brain homogenates analysis of enzyme activities and levels of the oxidative phosphorylation system, oxidative stress and neuroinflammation were performed. Results The mean age of the mice at the end of the intervention period did not differ between groups: 5.2 ± 0.2 (WT-Sed), 5.2 ± 0.1 (WT-Ex), 5.3 ± 0.1 (Hq-Sed), and 5.3 ± 0.1 months (Hq-Ex) (p = 0.489). A significant group effect was found for most variables indicating cerebellar dysfunction in Hq mice compared with WT mice irrespective of training status. However, exercise intervention did not counteract the negative effects of the disease at the cerebellum level (i.e., no differences for Hq-Ex vs. Hq-Sed). On the contrary, in brain, the activity of complex V was higher in both Hq mice groups in comparison with WT animals (p < 0.001), and post hoc analysis also revealed differences between sedentary and trained Hq mice. Conclusion A combined training program initiated when neurological symptoms and neuron death are already apparent is unlikely to promote neuroprotection in the cerebellum of Hq model of mitochondrial disorders, but it induces higher complex V activity in the brain.
Collapse
Affiliation(s)
- Miguel Fernández-de la Torre
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
| | - Carmen Fiuza-Luces
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
| | - Pedro L Valenzuela
- Physiology Unit, Department of Systems Biology, University of Alcalá, Madrid, Spain
| | - Sara Laine-Menéndez
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain
| | - Joaquín Arenas
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
| | - Miguel A Martín
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
| | - Doug M Turnbull
- Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, The Medical School Newcastle University, Newcastle upon Tyne, United Kingdom
| | - Alejandro Lucia
- Faculty of Sport Sciences, European University of Madrid, Madrid, Spain.,Spanish Network for Biomedical Research in Fragility and Healthy Aging (CIBERFES), Madrid, Spain
| | - María Morán
- Mitochondrial and Neuromuscular Diseases Laboratory, Instituto de Investigación Sanitaria Hospital '12 de Octubre' ('imas12'), Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain
| |
Collapse
|
33
|
González-Quintana A, Trujillo-Tiebas MJ, Fernández-Perrone AL, Blázquez A, Lucia A, Morán M, Ugalde C, Arenas J, Ayuso C, Martín MA. Uniparental isodisomy as a cause of mitochondrial complex I respiratory chain disorder due to a novel splicing NDUFS4 mutation. Mol Genet Metab 2020; 131:341-348. [PMID: 33093004 DOI: 10.1016/j.ymgme.2020.10.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 09/16/2020] [Accepted: 10/12/2020] [Indexed: 01/21/2023]
Abstract
Uniparental disomy (UPD) is an underestimated cause of autosomal recessive disorders. In this study, we aim to raise awareness about the possibility of UPD in mitochondrial disorders - where it is a hardly described event -, by functionally characterizing a novel variant in a structural subunit of complex I (CI) of the mitochondrial oxidative phosphorylation system. Using next-generation sequencing, we identified a new intronic homozygous c.350 + 5G > A variant in the NDUFS4 gene in a one-year-old girl (being alive at the age of 7) belonging to a non-consanguineous family presenting with encephalopathy, psychomotor delay, lactic acidosis and a single CI deficiency, a less severe phenotype than those previously reported in most NDUFS4 patients. One parent lacked the variant, and microsatellite genotyping showed complete paternal uniparental isodisomy of the non-imprinted chromosome 5. We demonstrated in patient's skeletal muscle and fibroblasts splicing abnormalities, low expression of NDUFS4, undetectable NDUFS4 protein, defects in cellular respiration (decreased oxygen consumption and ATP production), and impaired assembly or stability of mitochondrial supercomplexes containing CI. Our findings support that c.350 + 5G > A variant is pathogenic, and reinforce that UPD, although rare, should be considered as a possible cause of mitochondrial diseases in order to provide accurate genetic counselling.
Collapse
Affiliation(s)
- Adrián González-Quintana
- Mitochondrial Diseases Laboratory, Hospital Universitario '12 de Octubre', Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain
| | - María J Trujillo-Tiebas
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Department of Genetics, IIS-Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain
| | | | - Alberto Blázquez
- Mitochondrial Diseases Laboratory, Hospital Universitario '12 de Octubre', Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Alejandro Lucia
- Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain; Center for Biomedical Research Network on Frailty and Healthy Aging (CIBERFES), Madrid, Spain
| | - María Morán
- Mitochondrial Diseases Laboratory, Hospital Universitario '12 de Octubre', Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Cristina Ugalde
- Mitochondrial Diseases Laboratory, Hospital Universitario '12 de Octubre', Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Joaquín Arenas
- Mitochondrial Diseases Laboratory, Hospital Universitario '12 de Octubre', Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Carmen Ayuso
- Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Department of Genetics, IIS-Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain
| | - Miguel A Martín
- Mitochondrial Diseases Laboratory, Hospital Universitario '12 de Octubre', Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
| |
Collapse
|
34
|
Tort F, Barredo E, Parthasarathy R, Ugarteburu O, Ferrer-Cortès X, García-Villoria J, Gort L, González-Quintana A, Martín MA, Fernández-Vizarra E, Zeviani M, Ribes A. Biallelic mutations in NDUFA8 cause complex I deficiency in two siblings with favorable clinical evolution. Mol Genet Metab 2020; 131:349-357. [PMID: 33153867 DOI: 10.1016/j.ymgme.2020.10.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 10/09/2020] [Indexed: 01/08/2023]
Abstract
Isolated complex I (CI) deficiency is the most common cause of oxidative phosphorylation (OXPHOS) dysfunction. Whole-exome sequencing identified biallelic mutations in NDUFA8 (c.[293G > T]; [293G > T], encoding for an accessory subunit of CI, in two siblings with a favorable clinical evolution. The individuals reported here are practically asymptomatic, with the exception of slight failure to thrive and some language difficulties at the age of 6 and 9 years, respectively. These observations are remarkable since the vast majority of patients with CI deficiency, including the only NDUFA8 patient reported so far, showed an extremely poor clinical outcome. Western blot studies demonstrated that NDUFA8 protein was strongly reduced in the patients' fibroblasts and muscle extracts. In addition, there was a marked and specific decrease in the steady-state levels of CI subunits. BN-PAGE demonstrated an isolated defect in the assembly and the activity of CI with impaired supercomplexes formation and abnormal accumulation of CI subassemblies. Confocal microscopy analysis in fibroblasts showed rounder mitochondria and diminished branching degree of the mitochondrial network. Functional complementation studies demonstrated disease-causality for the identified mutation as lentiviral transduction with wild-type NDUFA8 cDNA restored the steady-state levels of CI subunits and completely recovered the deficient enzymatic activity in immortalized mutant fibroblasts. In summary, we provide additional evidence of the involvement of NDUFA8 as a mitochondrial disease-causing gene associated with altered mitochondrial morphology, CI deficiency, impaired supercomplexes formation, and very mild progression of the disease.
Collapse
Affiliation(s)
- Frederic Tort
- Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, IDIBAPS, CIBERER, Barcelona, Spain
| | | | | | - Olatz Ugarteburu
- Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, IDIBAPS, CIBERER, Barcelona, Spain
| | - Xenia Ferrer-Cortès
- Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, IDIBAPS, CIBERER, Barcelona, Spain
| | - Judit García-Villoria
- Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, IDIBAPS, CIBERER, Barcelona, Spain
| | - Laura Gort
- Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, IDIBAPS, CIBERER, Barcelona, Spain
| | - Adrián González-Quintana
- Laboratorio de Enfermedades Mitocondriales, Servicio de Bioquímica, Instituto de Investigación Hospital, 12 de Octubre (imas12), CIBERER, Madrid, Spain
| | - Miguel A Martín
- Laboratorio de Enfermedades Mitocondriales, Servicio de Bioquímica, Instituto de Investigación Hospital, 12 de Octubre (imas12), CIBERER, Madrid, Spain
| | | | - Massimo Zeviani
- MRC-Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | - Antonia Ribes
- Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clínic, IDIBAPS, CIBERER, Barcelona, Spain.
| |
Collapse
|
35
|
Reyes J, Toledo M, Michán C, Siles JA, Alhama J, Martín MA. Biofiltration of butyric acid: Monitoring odor abatement and microbial communities. Environ Res 2020; 190:110057. [PMID: 32805248 DOI: 10.1016/j.envres.2020.110057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Revised: 07/10/2020] [Accepted: 08/07/2020] [Indexed: 06/11/2023]
Abstract
The objective of this study is to evaluate comparatively the odor removal efficacy of two biofilters operated under different conditions and to identify taxonomically the microbial communities responsible for butyric acid degradation. Both biofiltration systems, which were filled with non-inoculated wood chips and exposed to gas streams containing butyric acid, were evaluated under different operational conditions (gas airflow and temperature) from the physical-chemical, microbiological and olfactometric points of view. The physical-chemical characterization showed the acidification of the packing material and the accumulation of butyric acid during the biofiltration process (<60 days). The removal efficacy was found to be 98-100% during the first 20 days of operation, even at high odor concentration. Changes in the operational temperature increased the odor load factor from 400 to 1400 ouE/m2·s, which led to the reduction of microbiota in the packing material, and a drastic drop of the odor removal efficacy. However, the progressive increase in gas airflow improved the biodegradation efficacy of butyric acid up to 88% with odor loadings as high as 33,000 ouE/m3, while a linear relationship between odor inlet load and removal capacity was also found. The analysis of the microbial community showed that Proteobacteria was the most abundant phylum along the biofiltration time (58-92%) and regardless of the operational conditions. Finally, principal component analysis applied to the physical-chemical and microbiological data set revealed significant differences between the two biofilters under study.
Collapse
Affiliation(s)
- J Reyes
- Chemical Engineering Department, University of Cordoba, Campus Universitario de Rabanales, Ctra. N-IV, Km 396, Building Marie Curie (C-3), 14071, Córdoba, Spain
| | - M Toledo
- Chemical Engineering Department, University of Cordoba, Campus Universitario de Rabanales, Ctra. N-IV, Km 396, Building Marie Curie (C-3), 14071, Córdoba, Spain
| | - C Michán
- Department of Biochemistry and Molecular Biology, University of Cordoba, Campus Universitario de Rabanales, Ctra. N-IV, Km 396, Building Severo Ochoa, 14071, Córdoba, Spain
| | - J A Siles
- Chemical Engineering Department, University of Cordoba, Campus Universitario de Rabanales, Ctra. N-IV, Km 396, Building Marie Curie (C-3), 14071, Córdoba, Spain
| | - J Alhama
- Department of Biochemistry and Molecular Biology, University of Cordoba, Campus Universitario de Rabanales, Ctra. N-IV, Km 396, Building Severo Ochoa, 14071, Córdoba, Spain
| | - M A Martín
- Chemical Engineering Department, University of Cordoba, Campus Universitario de Rabanales, Ctra. N-IV, Km 396, Building Marie Curie (C-3), 14071, Córdoba, Spain.
| |
Collapse
|
36
|
Pinós T, Andreu AL, Bruno C, Hadjigeorgiou GM, Haller RG, Laforêt P, Lucía A, Martín MA, Martinuzzi A, Navarro C, Oflazer P, Pouget J, Quinlivan R, Sacconi S, Scalco RS, Toscano A, Vissing J, Vorgerd M, Wakelin A, Martí R. Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry). Orphanet J Rare Dis 2020; 15:187. [PMID: 33054807 PMCID: PMC7558742 DOI: 10.1186/s13023-020-01455-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 06/29/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND International patient registries are of particular importance for rare disorders, as they may contribute to overcome the lack of knowledge derived from low number of patients and limited awareness of these diseases, and help to learn more about their geographical or population-based specificities, which is relevant for research purposes and for promoting better standards of care and diagnosis. Our objective was to create and implement a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) and to disseminate the knowledge of these disorders. RESULTS Teams from nine different countries (United Kingdom, Spain, Italy, France, Germany, Denmark, Greece, Turkey and USA) created a consortium that developed the first European registry dedicated to rare muscle glycogenoses. A work plan was implemented to design the database and platform that constitute the registry, by choosing clinical, genetics and molecular variables of interest, based on experience gained from previous national registries for similar metabolic disorders. Among dissemination activities, several teaching events were organized in different countries, especially those where the consortium considered the awareness of these diseases needs to be promoted among health professionals and patients. CONCLUSION EUROMAC represents a step forward in the knowledge of those disorders to which it is dedicated, and will have relevant clinical outcomes at the diagnostic, epidemiological, clinical and research level.
Collapse
Affiliation(s)
- Tomàs Pinós
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, and Research Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119, 08035, Barcelona, Catalonia, Spain
| | - Antoni L Andreu
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, and Research Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119, 08035, Barcelona, Catalonia, Spain
| | - Claudio Bruno
- Center of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | | | - Ronald G Haller
- Neuromuscular Center, Institute for Exercise and Environmental Medicine of Texas Health Presbyterian Hospital, Dallas, TX, USA
| | - Pascal Laforêt
- Nord/Est/Ile de France Neuromuscular Reference Center, Neurology Department, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France
- INSERM U1179, END-ICAP, Paris Saclay University, Paris, France
| | - Alejandro Lucía
- Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, and 12 de Octubre University Hospital Research Institute, ('imas12'), Madrid, Spain
| | - Miguel A Martín
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, and 12 de Octubre University Hospital Research Institute, ('imas12'), Madrid, Spain
| | - Andrea Martinuzzi
- Department of Conegliano-Pieve di Soligo, IRCCS Eugenio Medea-Associazione "La Nostra Famiglia" Scientific Institute, Bosisio Parini, Italy
| | | | - Piraye Oflazer
- Department of Neurology, Neuromuscular Unit, Istanbul University, Istanbul, Turkey
| | - Jean Pouget
- Centre de Référence Maladies Neuromusculaires, Assistance Publique-Hopitaux de Marseille, Marseille, France
| | - Ros Quinlivan
- MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, National Hospital, London, UK
| | | | - Renata S Scalco
- MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, National Hospital, London, UK
| | - Antonio Toscano
- Neurology and Neuromuscular Diseases Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - John Vissing
- Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Matthias Vorgerd
- Heimer Institute for Muscle Research, University Hospital Bergmannsheil Bochum, Bochum, Germany
| | | | - Ramon Martí
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, and Research Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119, 08035, Barcelona, Catalonia, Spain.
| |
Collapse
|
37
|
Santos-Lozano A, Calvo-Boyero F, López-Jiménez A, Cueto-Felgueroso C, Castillo-García A, Valenzuela PL, Arenas J, Lucia A, Martín MA. Can routine laboratory variables predict survival in COVID-19? An artificial neural network-based approach. Clin Chem Lab Med 2020; 58:e299-e302. [PMID: 33001844 DOI: 10.1515/cclm-2020-0730] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 09/09/2020] [Indexed: 01/07/2023]
Affiliation(s)
- Alejandro Santos-Lozano
- i+HeALTH, European University Miguel de Cervantes, Valladolid, Spain.,Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | | | - Ana López-Jiménez
- Clinical Biochemistry Department, Hospital 12 de Octubre, Madrid, Spain
| | | | | | | | - Joaquín Arenas
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain
| | - Alejandro Lucia
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain.,Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.,Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES), Madrid, Spain
| | - Miguel A Martín
- Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain.,Mitochondrial Disorders Laboratory, "Hospital 12 de Octubre" and Spanish Biomedical Network for Rare Disorders (CIBERER), Madrid, Spain
| | -
- i+HeALTH, European University Miguel de Cervantes, Valladolid, Spain
| |
Collapse
|
38
|
Rodríguez-Gómez I, Santalla A, Diez-Bermejo J, Munguía-Izquierdo D, Alegre LM, Nogales-Gadea G, Arenas J, Martín MA, Lucia A, Ara I. Sex Differences and the Influence of an Active Lifestyle on Adiposity in Patients with McArdle Disease. Int J Environ Res Public Health 2020; 17:ijerph17124334. [PMID: 32560448 PMCID: PMC7344565 DOI: 10.3390/ijerph17124334] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 06/11/2020] [Accepted: 06/13/2020] [Indexed: 11/30/2022]
Abstract
McArdle disease (glycogenosis-V) is associated with exercise intolerance, however, how it affects an important marker of cardiometabolic health as it is adiposity remains unknown. We evaluated the association between physical activity (PA) and adiposity in patients with McArdle disease. We assessed 199 adults of both sexes (51 McArdle patients (36 ± 11 years) and 148 healthy controls (35 ± 10 years)). Body fat (BF) was determined using dual-energy X-ray absorptiometry (DXA) method and each patient’s PA was assessed with the International PA Questionnaire (IPAQ). Although body mass index values did not differ between patients and controls, McArdle patients had significantly higher values of BF in all body regions (p < 0.05) and higher risk of suffering obesity (odds ratio (OR): 2.54, 95% confidence interval (95% CI): 1.32–4.88). Male patients had higher BF and obesity risk (OR: 3.69, 95% CI: 1.46−9.34) than their sex-matched controls, but no differences were found within the female sex (p < 0.05). In turn, active female patients had lower trunk BF than their inactive peers (p < 0.05). Males with McArdle seem to have adiposity problems and a higher risk of developing obesity than people without the condition, while female patients show similar or even better levels in the trunk region with an active lifestyle. Therefore, special attention should be given to decrease adiposity and reduce obesity risk in males with McArdle disease.
Collapse
Affiliation(s)
- Irene Rodríguez-Gómez
- GENUD Toledo Research Group, Universidad de Castilla-La Mancha, 45071 Toledo, Spain; (I.R.-G.); (L.M.A.)
- CIBER of Frailty and Healthy Aging (CIBERFES), 28029 Madrid, Spain; (A.S.); (D.M.-I.); (A.L.)
| | - Alfredo Santalla
- CIBER of Frailty and Healthy Aging (CIBERFES), 28029 Madrid, Spain; (A.S.); (D.M.-I.); (A.L.)
- Department of Sport and Computer Science, Section of Physical Education and Sports, Faculty of Sport, Universidad Pablo de Olavide, 41013 Sevilla, Spain
| | - Jorge Diez-Bermejo
- Research Institute Hospital 12 de Octubre, 28041 Madrid, Spain; (J.D.-B.); (J.A.); (M.A.M.)
| | - Diego Munguía-Izquierdo
- CIBER of Frailty and Healthy Aging (CIBERFES), 28029 Madrid, Spain; (A.S.); (D.M.-I.); (A.L.)
- Department of Sport and Computer Science, Section of Physical Education and Sports, Faculty of Sport, Universidad Pablo de Olavide, 41013 Sevilla, Spain
| | - Luis M. Alegre
- GENUD Toledo Research Group, Universidad de Castilla-La Mancha, 45071 Toledo, Spain; (I.R.-G.); (L.M.A.)
- CIBER of Frailty and Healthy Aging (CIBERFES), 28029 Madrid, Spain; (A.S.); (D.M.-I.); (A.L.)
| | - Gisela Nogales-Gadea
- Department of Neurosciences, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol I Campus Can Ruti, Universitat Autònoma de Barcelona, 08041 Badalona, Spain;
- CIBER of Rare Disorders (CIBERER), 28029 Madrid, Spain
| | - Joaquín Arenas
- Research Institute Hospital 12 de Octubre, 28041 Madrid, Spain; (J.D.-B.); (J.A.); (M.A.M.)
- CIBER of Rare Disorders (CIBERER), 28029 Madrid, Spain
| | - Miguel A. Martín
- Research Institute Hospital 12 de Octubre, 28041 Madrid, Spain; (J.D.-B.); (J.A.); (M.A.M.)
- CIBER of Rare Disorders (CIBERER), 28029 Madrid, Spain
| | - Alejandro Lucia
- CIBER of Frailty and Healthy Aging (CIBERFES), 28029 Madrid, Spain; (A.S.); (D.M.-I.); (A.L.)
- School of Research and Doctorate Studies, Universidad Europea de Madrid, 28670 Madrid, Spain
| | - Ignacio Ara
- GENUD Toledo Research Group, Universidad de Castilla-La Mancha, 45071 Toledo, Spain; (I.R.-G.); (L.M.A.)
- CIBER of Frailty and Healthy Aging (CIBERFES), 28029 Madrid, Spain; (A.S.); (D.M.-I.); (A.L.)
- Correspondence: ; Tel.: +34-925-268-800 (ext. 5543)
| |
Collapse
|
39
|
Lobo-Jarne T, Pérez-Pérez R, Fontanesi F, Timón-Gómez A, Wittig I, Peñas A, Serrano-Lorenzo P, García-Consuegra I, Arenas J, Martín MA, Barrientos A, Ugalde C. Multiple pathways coordinate assembly of human mitochondrial complex IV and stabilization of respiratory supercomplexes. EMBO J 2020; 39:e103912. [PMID: 32511785 DOI: 10.15252/embj.2019103912] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 04/20/2020] [Accepted: 05/06/2020] [Indexed: 12/28/2022] Open
Abstract
Mitochondrial respiratory chain complexes I, III, and IV can associate into larger structures termed supercomplexes or respirasomes, thereby generating structural interdependences among the individual complexes yet to be understood. In patients, nonsense mutations in complex IV subunit genes cause severe encephalomyopathies randomly associated with pleiotropic complex I defects. Using complexome profiling and biochemical analyses, we have explored the structural rearrangements of the respiratory chain in human cell lines depleted of the catalytic complex IV subunit COX1 or COX2. In the absence of a functional complex IV holoenzyme, several supercomplex I+III2 species coexist, which differ in their content of COX subunits and COX7A2L/HIGD2A assembly factors. The incorporation of an atypical COX1-HIGD2A submodule attenuates supercomplex I+III2 turnover rate, indicating an unexpected molecular adaptation for supercomplexes stabilization that relies on the presence of COX1 independently of holo-complex IV formation. Our data set the basis for complex I structural dependence on complex IV, revealing the co-existence of alternative pathways for the biogenesis of "supercomplex-associated" versus individual complex IV, which could determine physiological adaptations under different stress and disease scenarios.
Collapse
Affiliation(s)
- Teresa Lobo-Jarne
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | | | - Flavia Fontanesi
- Department of Biochemistry, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Alba Timón-Gómez
- Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Ilka Wittig
- SFB 815 Core Unit, Functional Proteomics, Goethe-Universität, Frankfurt am Main, Germany
| | - Ana Peñas
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | | | - Inés García-Consuegra
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, Spain
| | - Joaquín Arenas
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, Spain
| | - Miguel A Martín
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, Spain
| | - Antoni Barrientos
- Department of Biochemistry, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Cristina Ugalde
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, Spain
| |
Collapse
|
40
|
Reyes J, Gutiérrez MC, Toledo M, Vera L, Sánchez L, Siles JA, Martín MA. Environmental performance of an industrial biofilter: Relationship between photochemical oxidation and odorous impacts. Environ Res 2020; 183:109168. [PMID: 32004831 DOI: 10.1016/j.envres.2020.109168] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2019] [Revised: 12/20/2019] [Accepted: 01/22/2020] [Indexed: 06/10/2023]
Abstract
Biological techniques are widely used to treat gaseous streams derived from waste treatment plants. The generation of volatile organic compounds (VOCs) is one of the principal pollution sources in composting facilities from which nuisance odours are released. In addition, the generation of photochemical smog with other gases such as NOX can produce ozone at ground level due to their photochemical ozone creation potential (POCP). In this work, the performance of an industrial biofilter was evaluated from an environmental point of view. Specifically, this study evaluated the potential impact in terms of photochemical oxidation and odour emission derived from composting in a vessel under four different aeration conditions. Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS) was used to perform the chemical characterisation of the gaseous streams, while dynamic olfactometry was used to carry out the sensorial analysis. A total of 95 compounds belonging to 12 different families of VOCs were selected. Principal component analysis revealed the influence of each VOC family on each impact category and explained 88% of the total variance. Multivariate regression was used to study the correlation between photochemical oxidation and odour impact, which has never been reported before. The correlations obtained (r ≥ 0.97) evidenced the direct relationship between these two impacts. Photochemical oxidation and odour emission were proven to be important environmental impacts derived from composting facilities, whose abatement might be carried out by biofiltration systems.
Collapse
Affiliation(s)
- J Reyes
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie (C-3), 14071, Córdoba, Spain
| | - M C Gutiérrez
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie (C-3), 14071, Córdoba, Spain
| | - M Toledo
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie (C-3), 14071, Córdoba, Spain
| | - L Vera
- Odournet SL, Av. Corts Catalanes, 5-7,·Nave 3, Parc Empresarial Trade Center, 08173, Sant Cugat del Vallès, Barcelona, Spain
| | - L Sánchez
- Department of Inorganic Chemistry and Chemical Engineering, Area of Inorganic Chemistry, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie (C-3), 14071, Córdoba, Spain
| | - J A Siles
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie (C-3), 14071, Córdoba, Spain
| | - M A Martín
- Department of Inorganic Chemistry and Chemical Engineering, Area of Chemical Engineering, University of Cordoba, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie (C-3), 14071, Córdoba, Spain.
| |
Collapse
|
41
|
Rodríguez-López C, García-Cárdaba LM, Blázquez A, Serrano-Lorenzo P, Gutiérrez-Gutiérrez G, San Millán-Tejado B, Muelas N, Hernández-Laín A, Vílchez JJ, Gutiérrez-Rivas E, Arenas J, Martín MA, Domínguez-González C. Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia. J Med Genet 2020; 57:643-646. [PMID: 32161153 DOI: 10.1136/jmedgenet-2019-106649] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 02/06/2020] [Accepted: 02/22/2020] [Indexed: 11/03/2022]
Abstract
BACKGROUND Mitochondrial progressive external ophthalmoplegia (PEO) encompasses a broad spectrum of clinical and genetic disorders. We describe the phenotypic subtypes of PEO and its correlation with molecular defects and propose a diagnostic algorithm. METHODS Retrospective analysis of the clinical, pathological and genetic features of 89 cases. RESULTS Three main phenotypes were found: 'pure PEO' (42%), consisting of isolated palpebral ptosis with ophthalmoparesis; Kearns-Sayre syndrome (10%); and 'PEO plus', which associates extraocular symptoms, distinguishing the following subtypes: : myopathic (33%), bulbar (12%) and others (3%). Muscle biopsy was the most accurate test, showing mitochondrial changes in 95%. Genetic diagnosis was achieved in 96% of the patients. Single large-scale mitochondrial DNA (mtDNA) deletion was the most frequent finding (63%), followed by multiple mtDNA deletions (26%) due to mutations in TWNK (n=8), POLG (n=7), TK2 (n=6) or RRM2B (n=2) genes, and point mtDNA mutations (7%). Three new likely pathogenic mutations were identified in the TWNK and MT-TN genes. CONCLUSIONS Phenotype-genotype correlations cannot be brought in mitochondrial PEO. Muscle biopsy should be the first step in the diagnostic flow of PEO when mitochondrial aetiology is suspected since it also enables the study of mtDNA rearrangements. If no mtDNA deletions are identified, whole mtDNA sequencing should be performed.
Collapse
Affiliation(s)
| | | | - Alberto Blázquez
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.,Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain
| | - Pablo Serrano-Lorenzo
- Mitochondrial Disorders Research Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Comunidad de Madrid, Spain
| | | | | | - Nuria Muelas
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.,Neurology, Hospital Universitari i Politecnic La Fe, Valencia, Valenciana, Spain
| | - Aurelio Hernández-Laín
- Pathology, Neuropathology Section, Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Spain
| | - Juan J Vílchez
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.,Neuromuscular Diseases Unit, Neurology Department, Hospital Universitari i Politecnic La Fe, Valencia, Valenciana, Spain.,Neuromuscular and Ataxias Research Group, Instituto de Investigacion Sanitaria La Fe, Valencia, Spain
| | | | - Joaquín Arenas
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.,Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain
| | - Miguel A Martín
- Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain .,Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain
| | - Cristina Domínguez-González
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.,Mitochondrial Disorders Research Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Comunidad de Madrid, Spain.,Neuromuscular Unit, Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Spain
| |
Collapse
|
42
|
Hamraoui K, Gil A, El Bari H, Siles JA, Chica AF, Martín MA. Evaluation of hydrothermal pretreatment for biological treatment of lignocellulosic feedstock (pepper plant and eggplant). Waste Manag 2020; 102:76-84. [PMID: 31669677 DOI: 10.1016/j.wasman.2019.10.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 09/13/2019] [Accepted: 10/09/2019] [Indexed: 06/10/2023]
Abstract
Plant residues are an important source of organic matter that can be degraded by aerobic or anaerobic biological processes. However, due to the presence of lignocellulosic material, these residues are not easily biodegradable. Greenhouse crops, such as pepper and eggplant, generate large amounts of this type of waste after harvesting. In this study, a hydrothermal pretreatment was applied at 120 °C and different times to evaluate the enhancement of C and N solubilization in these residues. The highest solubilization of C was obtained at 40 min, as no significant increases were observed at higher times (100% and 68% for pepper plant [PP] and eggplant [EP], respectively). The solubilization of N shows a linear behavior (PP r2 = 0.9670 and EP r2 = 0.9395). Aerobic and anaerobic biodegradability were also evaluated, with better results found for the anaerobic digestion of the pretreated substrates. The nutrients balance with anaerobic co-digestion of both pretreated substrates (50:50% wt) improved methane production by 1.4 and 1.8 with respect to the substrates individually.
Collapse
Affiliation(s)
- K Hamraoui
- Renewable Energy and Environment Laboratory-Faculty of Sciences Ibn Tofail, Kénitra, Morocco
| | - A Gil
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - H El Bari
- Renewable Energy and Environment Laboratory-Faculty of Sciences Ibn Tofail, Kénitra, Morocco
| | - J A Siles
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - A F Chica
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - M A Martín
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain.
| |
Collapse
|
43
|
Peralta S, González-Quintana A, Ybarra M, Delmiro A, Pérez-Pérez R, Docampo J, Arenas J, Blázquez A, Ugalde C, Martín MA. Novel ATAD3A recessive mutation associated to fatal cerebellar hypoplasia with multiorgan involvement and mitochondrial structural abnormalities. Mol Genet Metab 2019; 128:452-462. [PMID: 31727539 DOI: 10.1016/j.ymgme.2019.10.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 10/29/2019] [Accepted: 10/30/2019] [Indexed: 11/24/2022]
Abstract
Lethal neonatal encephalopathies are heterogeneous congenital disorders that can be caused by mitochondrial dysfunction. Biallelic large deletions in the contiguous ATAD3B and ATAD3A genes, encoding mitochondrial inner membrane ATPases of unknown function, as well as compound heterozygous nonsense and missense mutations in the ATAD3A gene have been recently associated with fatal neonatal cerebellar hypoplasia. In this work, whole exome sequencing (WES) identified the novel homozygous variant c.1217 T > G in ATAD3A, predicting a p.(Leu406Arg) substitution, in four siblings from a consanguineous family presenting with fatal neonatal cerebellar hypoplasia, seizures, axial hypotonia, hypertrophic cardiomyopathy, hepatomegaly, congenital cataract, and dysmorphic facies. Biochemical phenotypes of the patients included hyperlactatemia and hypocholesterolemia. Healthy siblings and parents were heterozygous for this variant, which is predicted to introduce a polar chain within the catalytic domain of ATAD3A that shortens its beta-sheet structure, presumably affecting protein stability. Accordingly, patient's fibroblasts with the homozygous variant displayed a specific reduction in ATAD3A protein levels associated with profound ultrastructural alterations of mitochondrial cristae and morphology. Our findings exclude the causative role of ATAD3B on this severe phenotype, expand the phenotypical spectrum of ATAD3A pathogenic variants and emphasize the vital role of ATAD3A in mitochondrial biogenesis.
Collapse
Affiliation(s)
- Susana Peralta
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain
| | - Adrián González-Quintana
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Marta Ybarra
- Servicio de Neonatología, Hospital Infantil La Paz, 28046 Madrid, Spain
| | - Aitor Delmiro
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Rafael Pérez-Pérez
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain
| | - Jorge Docampo
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Joaquín Arenas
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Alberto Blázquez
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| | - Cristina Ugalde
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain.
| | - Miguel A Martín
- Laboratorio de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, U723, 28029 Madrid, Spain
| |
Collapse
|
44
|
Garcia-Solaesa V, Serrano-Lorenzo P, Ramos-Arroyo MA, Blázquez A, Pagola-Lorz I, Artigas-López M, Arenas J, Martín MA, Jericó-Pascual I. A Novel Missense Variant Associated with A Splicing Defect in A Myopathic Form of PGK1 Deficiency in The Spanish Population. Genes (Basel) 2019; 10:genes10100785. [PMID: 31658606 PMCID: PMC6826351 DOI: 10.3390/genes10100785] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Revised: 10/04/2019] [Accepted: 10/08/2019] [Indexed: 11/16/2022] Open
Abstract
Phosphoglycerate kinase (PGK)1 deficiency is an X-linked inherited disease associated with different clinical presentations, sometimes as myopathic affectation without hemolytic anemia. We present a 40-year-old male with a mild psychomotor delay and mild mental retardation, who developed progressive exercise intolerance, cramps and sporadic episodes of rhabdomyolysis but no hematological features. A genetic study was carried out by a next-generation sequencing (NGS) panel of 32 genes associated with inherited metabolic myopathies. We identified a missense variant in the PGK1 gene c.1114G > A (p.Gly372Ser) located in the last nucleotide of exon 9. cDNA studies demonstrated abnormalities in mRNA splicing because this change abolishes the exon 9 donor site. This novel variant is the first variant associated with a myopathic form of PGK1 deficiency in the Spanish population.
Collapse
Affiliation(s)
- Virginia Garcia-Solaesa
- Department of Medical Genetics, Complejo Hospitalario de Navarra, IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain, (M.A.R.-A.).
| | - Pablo Serrano-Lorenzo
- Laboratorio de Enfermedades Mitocondriales y Neurometabólicas. Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain, (P.S.-L.).
| | - Maria Antonia Ramos-Arroyo
- Department of Medical Genetics, Complejo Hospitalario de Navarra, IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain, (M.A.R.-A.).
| | - Alberto Blázquez
- Laboratorio de Enfermedades Mitocondriales y Neurometabólicas. Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain, (P.S.-L.).
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28041 Madrid, Spain.
| | - Inmaculada Pagola-Lorz
- Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for Health Research), 31008 Pamplona, Spain, (I.P.-L.).
| | - Mercè Artigas-López
- Department of Medical Genetics, Complejo Hospitalario de Navarra, IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain, (M.A.R.-A.).
| | - Joaquín Arenas
- Laboratorio de Enfermedades Mitocondriales y Neurometabólicas. Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain, (P.S.-L.).
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28041 Madrid, Spain.
| | - Miguel A Martín
- Laboratorio de Enfermedades Mitocondriales y Neurometabólicas. Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain, (P.S.-L.).
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28041 Madrid, Spain.
| | - Ivonne Jericó-Pascual
- Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for Health Research), 31008 Pamplona, Spain, (I.P.-L.).
| |
Collapse
|
45
|
Robledo-Mahón T, Martín MA, Gutiérrez MC, Toledo M, González I, Aranda E, Chica AF, Calvo C. Sewage sludge composting under semi-permeable film at full-scale: Evaluation of odour emissions and relationships between microbiological activities and physico-chemical variables. Environ Res 2019; 177:108624. [PMID: 31422221 DOI: 10.1016/j.envres.2019.108624] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 07/12/2019] [Accepted: 08/02/2019] [Indexed: 06/10/2023]
Abstract
In the present study, physico-chemical characteristics, heavy metals content, odour emissions, microbial enumeration and enzymatic activities were analysed during industrial scale composting of sewage sludge partially pre-treated to evaluate the effect of a combined system of semi-permeable film and aeration on these parameters. The results related to physico-chemical parameters showed a decrease in total organic carbon (TOC), organic matter (OM), total carbon (TC) along the process. Volatile solids (VS) were also reduced, reaching 36% at 120 days, which is above the limit according to the current legislation. Similarly, metal content was found to be an important variable in the evolution of enzymatic activity, while lead (Pb), zinc (Zn), and nickel (Ni) were the most influential. Moreover, heavy metals were found below the limit of type B compost quality or European class 2 at the end of the process, which is suitable for agriculture soil. The odorous impact generated during the hydrolytic stage was reduced to an average value of 4 ouE/s. This suggests that, covered stage with the semi-permeable film, could be a viable solution to mitigate odour emissions. The highest temperature was reached at 10 days and it was favoured by semi-permeable film. Temperature promoted the presence of thermophilic bacteria and fungi and indicated an early biodegradation process mediated by microorganisms. Statistical analyses revealed a high correlation of physico-chemical variables with microbial activity. Thus, samples from the first 14 days were highly correlated with enzymatic activities such as β-glucosidase (Ac-βGlu), protease (Ac-Pr), and dehydrogenase (Ac-De), which have usually been involved in the hydrolysis of organic matter.
Collapse
Affiliation(s)
- T Robledo-Mahón
- Institute of Water Research, Department of Microbiology. University of Granada. Ramón Cajal nº 4, 18071 Granada, Spain
| | - M A Martín
- University of Cordoba (Spain) - Department of Inorganic Chemistry and Chemical Engineering. Campus Universitario de Rabanales. Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain.
| | - M C Gutiérrez
- University of Cordoba (Spain) - Department of Inorganic Chemistry and Chemical Engineering. Campus Universitario de Rabanales. Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - M Toledo
- University of Cordoba (Spain) - Department of Inorganic Chemistry and Chemical Engineering. Campus Universitario de Rabanales. Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - I González
- University of Cordoba (Spain) - Department of Inorganic Chemistry and Chemical Engineering. Campus Universitario de Rabanales. Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - E Aranda
- Institute of Water Research, Department of Microbiology. University of Granada. Ramón Cajal nº 4, 18071 Granada, Spain
| | - A F Chica
- University of Cordoba (Spain) - Department of Inorganic Chemistry and Chemical Engineering. Campus Universitario de Rabanales. Carretera N-IV, km 396, Edificio Marie Curie, 14071 Córdoba, Spain
| | - C Calvo
- Institute of Water Research, Department of Microbiology. University of Granada. Ramón Cajal nº 4, 18071 Granada, Spain
| |
Collapse
|
46
|
Toledo M, Márquez P, Siles JA, Chica AF, Martín MA. Co-composting of sewage sludge and eggplant waste at full scale: Feasibility study to valorize eggplant waste and minimize the odoriferous impact of sewage sludge. J Environ Manage 2019; 247:205-213. [PMID: 31247367 DOI: 10.1016/j.jenvman.2019.06.076] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Revised: 06/13/2019] [Accepted: 06/15/2019] [Indexed: 06/09/2023]
Abstract
Sewage sludge and bulking agent with small proportions of eggplant waste (EP) (4.7 and 8.6%) were co-composted at full scale to evaluate the feasibility of their joint valorization and to reduce the odorous impact during composting. In this sense, physico-chemical, respirometric and olfactometric variables were monitored throughout the co-composting process. The physico-chemical variables studied were related to each other to evaluate their effect on the quality of the final product and the odoriferous impact. It was observed that the reduction in nitrogen concentration was not parallel to the removal of organic matter, which influenced the odor concentration emitted. Furthermore, during the hydrolytic stage of the co-composting process, the odor concentration was lower when the agricultural waste content was highest (8.6% EP: 6317 and 8192 ouE/m3) in comparison with the lowest concentration of EP (4.7% EP: 9214 and 14720 ouE/m3) or without the addition of EP (reference composting pile: 10200 and 22500 ouE/m3). Although sewage sludge is more biodegradable than eggplant waste, the co-composting process was carried out under suitable conditions. Approximately 90 days were required to obtain a stabilized compost. Consequently, co-composting might be a suitable alternative to valorize EP and reduce the odoriferous impact of sewage sludge, with the consequent economic, social and environmental benefits.
Collapse
Affiliation(s)
- M Toledo
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - P Márquez
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - J A Siles
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - A F Chica
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain
| | - M A Martín
- University of Cordoba (Spain), Department of Inorganic Chemistry and Chemical Engineering, Campus Universitario de Rabanales, Carretera N-IV, Km 396, Edificio Marie Curie, 14071, Córdoba, Spain.
| |
Collapse
|
47
|
Llavero F, Arrazola Sastre A, Luque Montoro M, Martín MA, Arenas J, Lucia A, Zugaza JL. Small GTPases of the Ras superfamily and glycogen phosphorylase regulation in T cells. Small GTPases 2019; 12:106-113. [PMID: 31512989 DOI: 10.1080/21541248.2019.1665968] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Small GTPases, together with their regulatory and effector molecules, are key intermediaries in the complex signalling pathways that control almost all cellular processes, working as molecular switches to transduce extracellular cues into cellular responses that drive vital functions, such as intracellular transport, biomolecule synthesis, gene activation and cell survival. How all of these networks are linked to metabolic pathways is a subject of intensive study. Because any response to cellular action requires some form of energy input, elucidating how cells coordinate the signals that lead to a tangible response involving metabolism is central to understand cellular activities. In this review, we summarize recent advances in our understanding of the molecular basis of the crosstalk between small GTPases of the Ras superfamily, specifically Rac1 and Ras/Rap1, and glycogen phosphorylase in T lymphocytes. Abbreviations: ADCY: adenylyl cyclase; ADCY6: adenylyl cyclase 6; BCR: B cell receptor; cAMP: 3',5'-cyclic adenosine monophosphate; CRIB: Cdc42/Rac binding domain; DLPFC: dysfunction of the dorsolateral prefrontal cortex; EGFR: epidermal growth factor receptor; Epac2: exchange protein directly activated by cAMP; GDP: guanodine-5'-diphosphate; GPCRs: G protein-coupled receptors; GTP: guanodin-5'-triphosphate; IL2: interleukin 2; IL2-R: interleukin 2 receptor; JAK: janus kinases; MAPK: mitogen-activated protein kinase; O-GlcNAc: O-glycosylation; PAK1: p21 activated kinase 1; PI3K: phosphatidylinositol 3-kinase; PK: phosphorylase kinase; PKA: cAMP-dependent protein kinase A; PKCθ: protein kinase Cθ; PLCγ: phospholipase Cγ; Src: proto-oncogene tyrosine-protein kinase c; STAT: signal transducer and activator of transcription proteins.
Collapse
Affiliation(s)
- Francisco Llavero
- Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU , Leioa, Spain.,Faculty of Sport Sciences, Universidad Europea de Madrid , Madrid, Spain
| | - Alazne Arrazola Sastre
- Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU , Leioa, Spain.,Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, UPV/EHU , Leioa, Spain
| | - Miriam Luque Montoro
- Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU , Leioa, Spain
| | - Miguel A Martín
- Enfermedades Raras, Mitocondriales y Neuromusculares., Instituto de Investigación Hospital 12 de Octubre (i+12) , Madrid, Spain.,Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III , Madrid, Spain
| | - Joaquín Arenas
- Enfermedades Raras, Mitocondriales y Neuromusculares., Instituto de Investigación Hospital 12 de Octubre (i+12) , Madrid, Spain.,Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III , Madrid, Spain
| | - Alejandro Lucia
- Faculty of Sport Sciences, Universidad Europea de Madrid , Madrid, Spain.,Enfermedades Raras, Mitocondriales y Neuromusculares., Instituto de Investigación Hospital 12 de Octubre (i+12) , Madrid, Spain.,Center for Biomedical Network Research on Frailty and Healthy Aging (CIBER FES), Instituto de Salud Carlos III , Madrid, Spain
| | - José L Zugaza
- Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU , Leioa, Spain.,Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, UPV/EHU , Leioa, Spain.,IKERBASQUE, Basque Foundation for Science , Bilbao, Spain
| |
Collapse
|
48
|
Fiuza-Luces C, Valenzuela PL, Laine-Menéndez S, Fernández-de la Torre M, Bermejo-Gómez V, Rufián-Vázquez L, Arenas J, Martín MA, Lucia A, Morán M. Physical Exercise and Mitochondrial Disease: Insights From a Mouse Model. Front Neurol 2019; 10:790. [PMID: 31402893 PMCID: PMC6673140 DOI: 10.3389/fneur.2019.00790] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Accepted: 07/09/2019] [Indexed: 01/13/2023] Open
Abstract
Purpose: Mitochondrial diseases (MD) are among the most prevalent neuromuscular disorders. Unfortunately, no curative treatment is yet available. This study analyzed the effects of exercise training in an animal model of respiratory chain complex I deficiency, the Harlequin (Hq) mouse, which replicates the clinical features of this condition. Methods: Male heterozygous Harlequin (Hq/Y) mice were assigned to an “exercise” (n = 10) or a “sedentary” control group (n = 11), with the former being submitted to an 8 week combined exercise training intervention (aerobic + resistance training performed five times/week). Aerobic fitness, grip strength, and balance were assessed at the beginning and at the end of the intervention period in all the Hq mice. Muscle biochemical analyses (with results expressed as percentage of reference data from age/sex-matched sedentary wild-type mice [n = 12]) were performed at the end of the aforementioned period for the assessment of major molecular signaling pathways involved in muscle anabolism (mTOR activation) and mitochondrial biogenesis (proliferator activated receptor gamma co-activator 1α [PGC-1α] levels), and enzyme activity and levels of respiratory chain complexes, and antioxidant enzyme levels. Results: Exercise training resulted in significant improvements in aerobic fitness (−33 ± 13 m and 83 ± 43 m for the difference post- vs. pre-intervention in total distance covered in the treadmill tests in control and exercise group, respectively, p = 0.014) and muscle strength (2 ± 4 g vs. 17 ± 6 g for the difference post vs. pre-intervention, p = 0.037) compared to the control group. Higher levels of ribosomal protein S6 kinase beta-1 phosphorylated at threonine 389 (156 ± 30% vs. 249 ± 30%, p = 0.028) and PGC-1α (82 ± 7% vs. 126 ± 19% p = 0.032) were observed in the exercise-trained mice compared with the control group. A higher activity of respiratory chain complexes I (75 ± 4% vs. 95 ± 6%, p = 0.019), III (79 ± 5% vs. 97 ± 4%, p = 0.031), and V (77 ± 9% vs. 105 ± 9%, p = 0.024) was also found with exercise training. Exercised mice presented with lower catalase levels (204 ± 22% vs. 141 ± 23%, p = 0.036). Conclusion: In a mouse model of MD, a training intervention combining aerobic and resistance exercise increased aerobic fitness and muscle strength, and mild improvements were found for activated signaling pathways involved in muscle mitochondrial biogenesis and anabolism, OXPHOS complex activity, and redox status in muscle tissue.
Collapse
Affiliation(s)
- Carmen Fiuza-Luces
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain
| | - Pedro L Valenzuela
- Physiology Unit, Systems Biology Department, University of Alcalá, Madrid, Spain
| | - Sara Laine-Menéndez
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain
| | - Miguel Fernández-de la Torre
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain
| | - Verónica Bermejo-Gómez
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain
| | - Laura Rufián-Vázquez
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain
| | - Joaquín Arenas
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
| | - Miguel A Martín
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
| | - Alejandro Lucia
- Faculty of Sports Sciences, European University of Madrid, Madrid, Spain.,Spanish Network for Biomedical Research in Fragility and Healthy Aging (CIBERFES), Madrid, Spain
| | - María Morán
- Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital 12 de Octubre (i+12), Madrid, Spain.,Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Madrid, Spain
| |
Collapse
|
49
|
Calvo AC, Cibreiro GA, Merino PT, Roy JF, Galiana A, Rufián AJ, Cano JM, Martín MA, Moreno L, Larrodé P, Vázquez PC, Galán L, Mora J, Muñoz-Blanco JL, Muñoz MJ, Zaragoza P, Pegoraro E, Sorarù G, Mora M, Lunetta C, Penco S, Tarlarini C, Esteban J, Osta R, Redondo AG. Collagen XIX Alpha 1 Improves Prognosis in Amyotrophic Lateral Sclerosis. Aging Dis 2019; 10:278-292. [PMID: 31011479 PMCID: PMC6457048 DOI: 10.14336/ad.2018.0917] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 09/17/2018] [Indexed: 12/13/2022] Open
Abstract
The identification of more reliable diagnostic or prognostic biomarkers in age-related neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), is urgently needed. The objective in this study was to identify more reliable prognostic biomarkers of ALS mirroring neurodegeneration that could be of help in clinical trials. A total of 268 participants from three cohorts were included in this study. The muscle and blood cohorts were analyzed in two cross-sectional studies, while the serial blood cohort was analyzed in a longitudinal study at 6-monthly intervals. Fifteen target genes and fourteen proteins involved in muscle physiology and differentiation, metabolic processes and neuromuscular junction dismantlement were studied in the three cohorts. In the muscle biopsy cohort, the risk for a higher mortality in an ALS patient that showed high Collagen type XIX, alpha 1 (COL19A1) protein levels and a fast progression of the disease was 70.5% (P < 0.05), while in the blood cohort, this risk was 20% (P < 0.01). In the serial blood cohort, the linear mixed model analysis showed a significant association between increasing COL19A1 gene levels along disease progression and a faster progression during the follow-up period of 24 months (P < 0.05). Additionally, higher COL19A1 levels and a faster progression increased 17.9% the mortality risk (P < 0.01). We provide new evidence that COL19A1 can be considered a prognostic biomarker that could help the selection of homogeneous groups of patients for upcoming clinical trial and may be pointed out as a promising therapeutic target in ALS.
Collapse
Affiliation(s)
- Ana C Calvo
- 1LAGENBIO (Laboratory of Genetics and Biochemistry), Faculty of Veterinary-IIS, IA2-CITA, University of Zaragoza, Zaragoza, Spain
| | - Gabriela Atencia Cibreiro
- 2Neurology Department, ALS Unit, CIBERER U-723, Health Research Institute, October 12th Hospital "IIS I+12", Madrid, Spain
| | - Paz Torre Merino
- 2Neurology Department, ALS Unit, CIBERER U-723, Health Research Institute, October 12th Hospital "IIS I+12", Madrid, Spain
| | - Juan F Roy
- 3Ferkauf Graduate School of Psychology, Yeshiva University, NY 10461, USA
| | - Adrián Galiana
- 4Servicio de Reumatología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - Alexandra Juárez Rufián
- 2Neurology Department, ALS Unit, CIBERER U-723, Health Research Institute, October 12th Hospital "IIS I+12", Madrid, Spain
| | - Juan M Cano
- 5Orthopaedic Surgery Department, October 12th Hospital, Madrid, Spain
| | - Miguel A Martín
- 6Grupo Enfermedades Mitocondriales y Neuromusculares, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), U723-CIBERER, Madrid, España
| | - Laura Moreno
- 1LAGENBIO (Laboratory of Genetics and Biochemistry), Faculty of Veterinary-IIS, IA2-CITA, University of Zaragoza, Zaragoza, Spain
| | - Pilar Larrodé
- 1LAGENBIO (Laboratory of Genetics and Biochemistry), Faculty of Veterinary-IIS, IA2-CITA, University of Zaragoza, Zaragoza, Spain
| | - Pilar Cordero Vázquez
- 2Neurology Department, ALS Unit, CIBERER U-723, Health Research Institute, October 12th Hospital "IIS I+12", Madrid, Spain
| | - Lucía Galán
- 7Neurology Department, ALS Unit, Clínico Universitario San Carlos Hospital, Madrid, Spain
| | - Jesús Mora
- 8Neurology Department, ALS Unit, Carlos III Hospital, Madrid, Spain
| | - José L Muñoz-Blanco
- 9Neurology Department, ALS Unit, Health Research Institute, Gregorio Marañón Hospital "IISGM", Madrid, Spain
| | - María J Muñoz
- 1LAGENBIO (Laboratory of Genetics and Biochemistry), Faculty of Veterinary-IIS, IA2-CITA, University of Zaragoza, Zaragoza, Spain
| | - Pilar Zaragoza
- 1LAGENBIO (Laboratory of Genetics and Biochemistry), Faculty of Veterinary-IIS, IA2-CITA, University of Zaragoza, Zaragoza, Spain
| | - Elena Pegoraro
- 10Neurological Clinic, Department of Neurosciences, University of Padova, Padova, Italy
| | - Gianni Sorarù
- 10Neurological Clinic, Department of Neurosciences, University of Padova, Padova, Italy
| | - Marina Mora
- 11Muscle Cell Biology Laboratory, Neuromuscular Diseases and Neuroimmunology Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy
| | - Christian Lunetta
- 12NEMO (NEuroMuscular Omnicentre) Clinical Center, Fondazione Serena Onlus, Milan, Italy
| | - Silvana Penco
- 13Medical Genetics Unit, Department of Laboratory Medicine, Niguarda Ca' Granda Hospital, Milan, Italy
| | - Claudia Tarlarini
- 13Medical Genetics Unit, Department of Laboratory Medicine, Niguarda Ca' Granda Hospital, Milan, Italy
| | - Jesús Esteban
- 2Neurology Department, ALS Unit, CIBERER U-723, Health Research Institute, October 12th Hospital "IIS I+12", Madrid, Spain
| | - Rosario Osta
- 1LAGENBIO (Laboratory of Genetics and Biochemistry), Faculty of Veterinary-IIS, IA2-CITA, University of Zaragoza, Zaragoza, Spain
| | - Alberto García Redondo
- 2Neurology Department, ALS Unit, CIBERER U-723, Health Research Institute, October 12th Hospital "IIS I+12", Madrid, Spain
| |
Collapse
|
50
|
Gil A, Siles JA, Márquez P, Gutiérrez MC, Martín MA. Optimizing the selection of organic waste for biomethanization. Environ Technol 2019; 40:564-575. [PMID: 29072111 DOI: 10.1080/09593330.2017.1397769] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Accepted: 10/22/2017] [Indexed: 06/07/2023]
Abstract
This study evaluates the feasibility of using simultaneous mass balances of different nutrients as a tool for optimizing feeding composition in anaerobic digestion. Different ratios, among them total chemical oxygen demand/total Kjeldahl nitrogen (TCOD/TKN) and soluble chemical oxygen demand/TCOD (SCOD/TCOD), were assessed. The TCOD/total volatile solids (TVS) ratio was 1.73 kg O2/kg TVS, while, with the exception of the sewage sludge, pig slurry and animal wastes, a linear relationship was established between phosphorus and nitrogen (0.06 kg P/kg TKN (R2 = 0.9045)). The study was applied to different mixtures of waste (cucumber, quince, tomato, strawberry waste, vinasse, glycerol, tomato plant, pig slurry, sewage sludge, fish waste, landfill leachate and viscera). The mass balance was performed for 50 mixtures chosen at random, containing three different wastes. After evaluating the theoretical optimal values determined by the mass balances, the most promising data were compared with the experimental results of the anaerobic co-digestion of one of the three waste mixtures. As predicted by the mass balances, the codigestion of glycerol, strawberry extrudate and fish waste (41:54:4 in VS) improved methane production to a maximum value of 0.308 m3 CH4/kg TVSadded for an organic loading rate of 0.62-4.26 kg TVS/m3·d.
Collapse
Affiliation(s)
- A Gil
- a Department of Chemical Engineering , Campus Universitario de Rabanales, University of Cordoba , Cordoba , Spain
| | - J A Siles
- a Department of Chemical Engineering , Campus Universitario de Rabanales, University of Cordoba , Cordoba , Spain
| | - P Márquez
- a Department of Chemical Engineering , Campus Universitario de Rabanales, University of Cordoba , Cordoba , Spain
| | - M C Gutiérrez
- a Department of Chemical Engineering , Campus Universitario de Rabanales, University of Cordoba , Cordoba , Spain
| | - M A Martín
- a Department of Chemical Engineering , Campus Universitario de Rabanales, University of Cordoba , Cordoba , Spain
| |
Collapse
|